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Abstract

Respiratory syncytial virus (RSV) is the most common cause of acute lower
respiratory tract infection in young children worldwide, accounting for an estimated 33.8
million cases of respiratory disease, over 3 million of which require hospitalization, and
between 66,000 and 199,000 deaths in this susceptible population. Additionally, severe
RSV infection early in life is associated with an increased risk of wheeze and other
airway disorders later in life. Despite this, there is currently no vaccine or economically
reasonable prophylactic regimen to prevent infection. While disease is typically more
severe in infancy RSV can infect throughout the lifespan repeatedly as the body does
not develop protective immunity during primary or subsequent infection. The
mechanisms behind this incomplete immunity are unclear.
RSV has been reported to infect numerous extra-epithelial cell types.
Interestingly, viral infection in human mesenchymal stem cells (MSCs) has been
reported, but the consequences are poorly understood. MSCs are an immune
regulatory cell population present in nearly every organ including the nasal mucosa and
the lung. They play a role in regulating immune responses and mediating tissue repair.
In the following studies we sought to determine whether RSV infection of MSCs
enhances their immune regulatory functions and contributes to RSV-associated lung
disease.
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RSV was shown to replicate in human MSCs by fluorescence microscopy,
plaque assay, and expression of RSV transcripts. RSV-infected MSCs showed
differentially altered expression of cytokines and chemokines such as IL-1β, IL-6, IL-8
and SDF-1 compared to normal human bronchial epithelial cells. Notably, RSV-infected
MSCs exhibited significantly increased expression of IFN-β (~100-fold) and
indoleamine-2,3-dioxygenase (IDO) (~70-fold) compared with mock-infected MSCs. IDO
was identified in cytosolic protein of infected cells by Western blots and enzymatic
activity was detected by tryptophan catabolism assay. Treatment of PBMCs with culture
supernatants from RSV-infected MSCs reduced their proliferation in a dose dependent
manner. This effect on PBMC activation was reversed by treatment of MSCs with the
IDO inhibitors 1-methyltryptophan and vitamin K3 during RSV infection.
We also demonstrated the pathway leading to IDO expression in RSV infected
MSCs. Neutralizing IFN-β prevented IDO expression and activity indicating its role as a
viral response factor perhaps “high jacked” by the virus in immune escape. Treatment of
MSCs with an endosomal TLR, but not a RIG-I, inhibitor prevented IFN-β and IDO
expression. Additionally, TLR3/dsRNA complex inhibitor was able to block IFN-β
stimulation, while a TLR7/8/9 inhibitory ODN did not, suggesting that endosomal TLR3
detection of RSV dsRNA was leading to IFN-β and IDO expression. Together, these
findings indicate that RSV infection of MSCs triggers their immune regulatory function
via TLR3 recognition of dsRNA, upregulating IFN-β expression and IDO activity,
ultimately affecting immune cell proliferation. This finding may account for the lack of
protective RSV immunity and consequent repeated infections throughout one’s lifetime.
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Chapter 1: Introduction and Background

1.1 Significance of respiratory syncytial virus
RSV infections occur in nearly all children by the age of 3 years and reinfection
even within the same season is common. This is due to the lack of development of a
protective immune response including neutralizing antibodies to the virus [1], and
neonatal infection may occur even in the presence of maternal antibodies in the serum
specific to RSV [2]. At present no approved vaccine exists and the only available
prophylaxis is the monthly injection of a costly monoclonal antibody as a passive
immunotherapy, which is limited in use to only those infants at high risk of respiratory
distress; including those that are immunocompromised or born with congenital heart
defects [3, 4]. This is due to the fact that while RSV infections generally manifest as a
mild cold in healthy individuals disease can be more severe in at risk neonates and
infants. Similarly, RSV can cause serious disease in susceptible immunocompromised
adult populations including transplant recipients, cancer patients, persons with AIDS
and the elderly; leading to lower respiratory infections including bronchiolitis and
pneumonia [5, 6]. Unlike the neonatal and infant populations there is no approved or
economical prophylaxis for these at risk adult populations.
In the United States RSV is estimated to be the cause of 24% of all lower
respiratory tract infection (LRTI)-associated hospitalizations of children less than 5
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years old, accounting for between 132,000-172,000 hospitalizations every year [7].
Populations at an increased risk of viral and bacterial infections such as preterm infants
and those with congenital respiratory or circulatory disorders are especially susceptible
to severe RSV-associated LRTI [8-10]. One study indicated that between 40% and 60%
of premature infants that were hospitalized for LRTI were suffering from RSV-related
illness [11]. Studies have shown that infants who develop severe RSV-associated LRTI
have decreased lung function and increased airway resistance [12]. Additionally, a longterm outcome study following infants hospitalized for RSV-related LRTI found that these
infants showed increased airway disease such as asthma and recurrent wheeze as well
as high serum anti-allergen IgE levels even 18 years after being hospitalized [13].
In addition to the increased risk of infection, preexisting congenital disorders
have been associated with significantly increased morbidity associated with RSV LRTI
[14]. Neonatal congenital heart disease (CHD) has been associated with significantly
higher mortality from RSV LRTI with an alarming 37% mortality rate for neonates born
with CHD versus 1.5% for those born without heart defects [15]. Also, the length of
hospitalization and incidence of hospital-acquired RSV infection is higher in CHD
neonates [8, 16]. Children who suffer from immune suppression, such as those with
human immunodeficiency virus (HIV) infections, are also at an increased risk of RSVassociated lung disease. One study found that HIV-infected children had a 92.3%
incidence rate of RSV-induced pneumonia compared with 68.8% in uninfected children
[17]. Severe RSV is associated with extended hospital stays and may require costly
medical interventions such as mechanical ventilation. A study involving infants under 1
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year old from 1997 to 2000 reported 311,077 hospitalizations resulting from RSV
bronchiolitis at an estimated cost of $3 billion [18].
Beyond its impact in mortality and morbidity of infants and children, RSV has also
been shown to be an important pathogen in aged populations, accounting for an
estimated 30% of respiratory related healthcare visits in individuals over the age of 65
[5] with a 8% mortality rate [19]. Additionally, reports suggest RSV is responsible for
between 8.2 and 25.4 hospitalizations per 10,000 patients over the age of 50 [20]. And
although it is typically considered a pediatric respiratory disease the number of deaths
annually attributed to RSV is markedly higher in adults over 65 years of age, with a
mortality rate two-fold higher than the rate in children under 5 [19]. Differences in
adaptive and innate immune system associated with aging may account for increased
susceptibility and mortality in aged populations [21].
1.2 Development of vaccines and therapeutics
Despite first being identified in the 1960’s there is currently no approved vaccine
for RSV. An early vaccination trial using a formalin-inactivated virus failed when the
treatment was associated with increased disease severity and mortality upon
subsequent natural infection [22]. The only approved measure to prevent RSVassociated disease is a passive immune treatment using a monoclonal antibody
designed to inhibit fusion of the virus to target cells [23]. This antibody, palivizumab,
also known by the brand name Synagis (MedImmune), is only prescribed to select highrisk neonates and infants such as those with CHD or chronic lung disease or those born
prematurely [4, 9, 24], as described previously. Despite being associated with
decreased hospitalization rates for RSV-associated bronchiolitis and pneumonia cost-
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benefit analyses suggest that it is not viable as a preventative treatment in healthy
infants, children, or adults or elderly [4, 9, 25].
Other vaccination efforts are currently in development and clinical trials including
a nanoparticle vaccine composed of an immunogenic fusion protein subunit [26] as well
as an RNA-interference based vaccine against RSV genes [27-29]. Additionally, an
alternative neutralizing antibody motavizumab (MED-254, MedImmune) has been
developed [30-32] but was not approved by the FDA due to lack of evidence that it
prevented RSV disease better than the current approved treatment and the increased
risk for adverse events at the injection site.
1.3 RSV structure and genes
Respiratory syncytial virus (RSV) is an enveloped single-stranded negativesense RNA virus of the Pneumovirus genus in subfamily pneumovirinae of the
Paramyxoviridae family. The defining characteristic of Paramyxoviridae viruses is a
fusion protein F that facilitates viral entry into host cell via membrane fusion. In addition
to the F protein RSV also displays two other surface glycoproteins in its envelope: the
small hydrophobic SH protein as well as the major surface glycoprotein G. Variability in
RSV G protein is used to differentiate human RSV into two subtypes: A and B. Of the
two, RSV subtype A is more predominant and virulent [33].
Structurally, RSV forms a spherical virion between 150 and 300 nm in diameter
with a lipid bilayer envelope formed during budding from the host cell [34]. Within the
viral envelope lies a nucleocapsid containing the viral genome as well as proteins
necessary for viral replication. After attachment, fusion, and uncoating the virus begins
replication in the cytoplasm of the infected cell. The virus’s RNA genome is just over
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15,000 nucleotides in length and codes for 11 proteins including the two nonstructural
proteins NS1 and NS2; the nucleoprotein N; a phosphoprotein P; the matrix protein M;
the three previously mentioned envelope proteins SH, G, and F; transcription factors
M2-1 and M2-2; and the large polymerase subunit protein L. In a similar fashion to other
non-segmented negative strand RNA viruses the genome of RSV serves as a template
for transcription of viral mRNAs and genomic replication. Replication occurs through
generation of a full-length antigenome, which is used as a template for genomic RNA
synthesis. Both the genome and antigenome are found in the cell cytosol tightly bound
to the N protein, which protects them from degradation by host cell ribonuclease activity.
A polymerase complex made up of the L, P, and M2 proteins facilitate both transcription
and replication [35]. NS1 and NS2 are not found within the virion nor are they required
for viral infection or replication, however they have been shown to enhance viral
infection through regulation of host cell antiviral responses [36-40]. In contrast,
pathogenesis of RSV is dependent on the function of the G protein [41], which facilitates
attachment of virus to host cell, and the F protein, which is necessary for fusion of virion
with the host cell membrane allowing entry. Syncytia formation for which the virus is
named is dependent on the F protein. Virus transmission from cell to cell may occur by
either syncytial formation through cell-cell fusion or through viral budding and
attachment to distal cells.
Mucosal cells of the airway epithelium are considered the chief target of RSV,
although infections in a number of other cell types have been reported both in vitro and
in vivo. Several cell surface receptors for RSV have been described: heparin-like
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glycosaminoglycans [42, 43]; toll-like receptor 4 (TLR4) and CD14 [44]; intercellular
adhesion molecule-1 (ICAM-1) [45]; and fractalkine receptor (CX3CR1) [46].
Following RSV infection epithelial cells produce proinflammatory cytokines and
chemokines, which recruit immune cells to the airway. The interaction of RSV with TLR4
activates the transcription factor NF-κB leading to the transcription of genes responsible
for the inflammatory response [47, 48]. Other members of the TLR family including the
endosomal TLR3 and TLR7/8 have also been reported to play role in immune
responses to RSV [49, 50]. Additionally, virus genome and transcripts are detected
through other pattern recognition receptors (PRR) such as RIG-I and MDA5 [8, 38],
which have also been shown to activate host immune responses.
1.4 Epidemiology of RSV
Although RSV infections may occur at any time of year outbreaks typically follow
a seasonal pattern and despite repeated infections individuals are susceptible to
reinfection each year. During the 2015-2016 RSV season infections began to increase
in October 2015 and continued through the New Year until starting to taper off in March
2016, ending in early May [51]. The exception to the seasonal outbreak pattern in the
United States is Florida, which has both an earlier onset and later tapering leading to an
extended RSV season. RSV outbreaks are typically due to one of the two major
antigenic groups, A or B, which vary in their RSV surface glycoprotein G [41]. Unlike
some other viruses, such as influenza, which undergo genome rearrangement to modify
surface antigens and thereby avoid immune detection RSV antigenicity does not vary
greatly from season to season. Rather than changing the surface proteins it is believed
that RSV avoids protective immunity by modulating the immune response during an
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infection such that reinfection is possible even within the same RSV season.
Understanding the various mechanisms that RSV uses to alter immunity may help
provide real solutions for the treatment and prevention of RSV infection and reinfection
and reduce the burden this virus puts on global public health.
1.5 Interactions with the immune system
RSV infections occur repeatedly throughout an individual’s lifetime, suggesting
that although there is an immune response to the virus it does not provide lasting
immunity. The 15 kilobase single-stranded genome of RSV codes for eleven proteins;
Several structural components which make up the nucleocapsid and receptors in the
envelope as well as two nonstructural genes which are not packaged in the virion.
These genes, nonstructural protein 1 and 2 (NS1 and NS2), are the most promoterproximal genes in the genome meaning they are the earliest and most heavily
transcribed [36, 37, 52]. NS2 and NS1 have been implicated to regulate a number of
host cellular processes. RSV NS2 has proteolytic functions and has been shown to be
involved in regulation of RNA synthesis. Additionally, it antagonizes the interferon
signaling by interfering with components of JAK-STAT pathway [38, 53, 54]. Similarly
NS1 has been found to interfere with the STAT1, TRAF3, and IKKε pathways [37, 40,
55, 56]. Both nonstructural proteins have been found to suppress type I, II, and III
interferons by both directly binding RIG-I as well as promoting ubiquitin-mediated
STAT2 degradation by the proteasomal pathway [38, 57-59]. Neither NS1 nor NS2 are
critical for viral replication [36].
Other viral proteins also play a role in preventing or delaying host cell detection
and response to infection. The phosphoprotein P and nucleoprotein N protect the viral
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genome from the host cell and are involved in the creation of inclusion bodies which
decrease type I interferon [60]. The envelope proteins F and G not only serve as viral
attachment and fusion mediators but have been found to be secreted and may play a
role in blocking antibodies that would otherwise bind to and neutralize the virus [61, 62].
Additionally, RSV G can bind to CX3CR1, the chemokine receptor, competing with it’s
ligand fractalkine [63]. G has also been implicated in the stimulation of suppressor of
cytokine signaling (SOCS) proteins 1 and 2, which in turn regulate interferon responses
[64]. Surface expression of TLR4 and intercellular adhesion molecule-1 (ICAM-1) is also
increased by infection with RSV [65, 66].
1.6 Extrapulmonary and extra-epithelial infections
In addition to the epithelial cells of the nasal mucosa and lower respiratory tract
RSV has been shown to infect a multitude of other cell types. In addition to a number of
non-respiratory tissues which may be infected in rare cases of severe disease [67] there
are a number of studies indicating that even during a normal RSV infection nonepithelial cells may be infected. For example there is evidence that pulmonary
endothelial cells may also be targets for RSV and infection may increase cell adhesion
molecules, increasing leukocyte adhesion and extravasation into the lung [66].
Additionally, RSV has been found to infect and replicate in a number of cells present at
the sites of infection including pulmonary macrophages [68, 69] as well as dendritic cells
[70-72]. Neutrophils, a cell type responsible for mediating rapid innate immune
responses to pathogens have also been isolated from the blood and bronchial-alveolar
lavages of RSV infected infants and shown to contain productive, replicating virus [7375]. Cells of the stroma have also been found to be a potential target for RSV. Freshly
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isolated bone marrow-derived MSCs were found to contain transcripts for the
nucleocapsid N gene and were found highly permissive to RSV in vitro [76]. These
findings suggest that perhaps a resident stromal cell type such as MSCs in the lung or
nasal mucosa could be an extra-epithelial target for RSV and contribute to RSVmediated regulation of the immune system.
1.7 Mesenchymal stem cells as immune regulatory cells
Mesenchymal stem cells (MSC, also known as multipotent stromal cells) are a
class of undifferentiated multipotent cells originally isolated from bone marrow [77, 78]
but have since been identified and isolated from numerous adult tissues including
adipose tissue, brain, muscle, as well as the airway mucosa [79-82]. Phenotypically
they are a fibroblast-like plastic-adherent cell characterized by their ability to
differentiate into adipocytes, chondrocytes, and osteocytes as well as a panel of surface
markers including CD105, CD90, CD44, and STRO-1. They serve as a readily available
reservoir of reparative cells for tissue regeneration; able to mobilize, proliferate and
differentiate into multiple lineages of cells in response to specific signals [83, 84].
In addition to their function in tissue maintenance and repair they have also been
identified as immune regulatory cells capable of secreting immune modulating factors
as well as interacting directly with immune and antigen presenting cells [85-89]. Studies
in allogeneic bone marrow transplantation recipients have found that co-transfusion of
MSCs with hematopoietic stem cells reduces the incidence and severity of graft-versushost disease post-transplantation [85, 90, 91]. MSCs have been found to suppress
immune responses of many immune cells types including T cells, B cells, natural killer
cells, granulocytes and dendritic cells. In T cells they have been found to inhibit antigen-
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specific T cell proliferation as well as cytotoxicity in addition to increasing the generation
of regulatory T cells. MSCs have also been shown to reduce the proliferation of B cells
in response to mitogen stimulation. They also influence cells of the innate immune
response, such as neutrophils in which they have been shown to impair respiratory
burst via IL-6 secretion [92].
1.8 Concluding remarks
The following work is designed to investigate and understand the role that may
MSCs play in RSV infection. To begin this study MSCs were first infected and analyzed
for permissiveness and productivity of RSV. Then inflammatory and antiviral response
factors were assayed to investigate the response MSCs had against RSV. Next the
effect on MSCs in terms of their immune regulatory role was explored and the
mechanisms behind these responses were investigated. Finally, a comparison of these
results to a common animal model of RSV, the mouse model, was completed. The
findings of this study suggest a role for RSV-infected MSCs in RSV immune evasion,
persistence, and recurrent infections.
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Chapter 2: Materials and Methods

2.1 Cell and virus lines
Cell lines used in the following experiments included the human epithelial cell line
HEp-2 (HeLa contaminant, ATCC #CCL-23), the human alveolar epithelial cell line A549
(ATCC #CCL-185), and the African green monkey kidney epithelial cell line Vero (ATCC
#CCL-81) which were each purchased from the American Type Culture Collection
(Manassas, VA), grown in Dulbecco’s modified Eagle’s medium (DMEM) with 5% fetal
bovine serum (FBS), L-glutamine, and the antibiotics penicillin and streptomycin at 100
units/ml and 100 μg/ml respectively. Additionally, two sources of human MSC lines were
used in these experiments: Umbilical cord blood derived MSCs were purchased from
Vitro Biopharma (Golden, CO) and bone marrow derived MSCs were obtained from the
Institute for Regenerative Medicine at Scott and White Texas A&M Health Science
Center (Temple, TX). MSCs were grown in complete MSC media made up of alpha
minimum essential media (αMEM) supplemented with 16.5% non-heat inactivated FBS,
Glutamax (Life Technologies, Carlsbad, CA), 100 units/ml penicillin, and 100 μg/ml
streptomycin. All experiments were performed with MSCs passaged fewer than 10
times. Normal human bronchial epithelial (NHBE) cells were purchased from Lonza
(Allendale, NJ) and grown in bronchial epithelial growth medium (BEGM, Lonza). No
NHBE cells were used beyond passage 5.
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RSV A2 was originally purchased from the ATCC (#VR1302). Recombinant RSV
A2 expressing green fluorescent protein (rgRSV) was provided by Dr. Mark Peeples
(Nationwide Children’s Hospital, Columbus, OH). Recombinant RSV A2 expressing
mKate2 and the F protein of RSV line 19 (rA2-KL19F) was generously provided by Dr.
Martin Moore (Emory University, Atlanta, GA). All virus infections were performed for 90
min at 37ºC with virus diluted in Opti-MEM supplemented with 2% FBS. Viral stocks
were initially propagated by infection of near-confluent HEp-2 cell monolayers with 0.1
to 0.2 MOI virus. Supernatants and cells were collected and subjected to one freezethaw cycle and then semi-clarified by centrifugation for 20 min at 1000 x g prior to snap
freezing and storage at -80ºC. These stocks were then used to produce purified virus by
infection of near-confluent HEp-2 cells with 0.1 to 0.2 MOI virus. After significant
cytopathic effects were observed (5 to 6 days post-infection) the supernatants were
collected and cells were scraped and briefly vortexed to release virions. Pelleted cells
and debris were discarded in bleach while semi-clarified supernatant was treated with
1M MgSO4 and transferred to an ultracentrifuge tube. A glycerol solution containing
30% glycerol in 0.1M MgSO4 and 50mM HEPES buffer was carefully added to the
bottom of the tube. Each tube was then spun in a Beckman ultracentrifuge at 11,600
RPM for 3 hours at 4ºC. Afterwards the supernatant was carefully removed and each
pellet was gently washed with 5ml OptiMEM to remove excess glycerol. Pelleted virus
was resuspended in virus buffer containing 0.1M MgSO4, 150mM NaCl, and 50mM
HEPES. Small aliquots were frozen and stored at -80ºC. Plaque forming unit assays
were performed in HEp-2 cells to determine the number of infective virions per ml. Virus
buffer alone was similarly frozen in small aliquots to be used as mock infection media.
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Ultraviolet (UV) inactivation of virus was performed using a UV Stratalinker 1800
(Stratagene, La Jolla, CA) by exposing virus resuspended in media to two rounds of 1
joule UV irradiation.
2.2 Virus quantification
Viral titers from cell culture and homogenized tissues were determined using a
plaque forming unit assay. Samples were centrifuged at 4°C for 10 min at 300 x g and
serially diluted with serum-free media for infection in HEp-2 cells plated in 24-well cell
culture plates and grown to 80% confluence. After an hour of infection at 37°C with
frequent rocking the infection media was replaced with DMEM containing 0.8%
methylcellulose, 5% FBS, L-glutamine, 100 units/ml penicillin, and 100 μg/ml
streptomycin. After five days of growth the overlay was removed and plaques were fixed
with 80% methanol overnight at 4°C. Fixative was removed and plaques were blocked
with 5% non-fat milk in phosphate-buffered saline (PBS) at room-temperature for 30
minutes. Plaques were labeled with a primary monoclonal antibody solution containing
1:2000 dilution of mouse anti-RSV F (AbD Serotec, MCA490) for 2 hours at room
temperature. Samples were washed three times for 5 min each and a solution of
horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody diluted to
1:2000 was added to plaques for an hour. Plaques were visualized using the 4CN
substrate (Kirkegaard and Perry Laboratories) and counted manually and multiplied by
the dilution factor to calculate the total number of plaque-forming units per mL of
supernatant.
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2.3 Ribonucleic acid analysis
RNA was isolated from cell culture or mouse lung tissue using the TRIzol
Reagent (Invitrogen) and chloroform/isopropanol precipitation method. After
resuspension of precipitated RNA pellets with DEPC-treated water (Invitrogen) RNA
was treated with DNase I (Roche, Germany) for 20 min. DNase enzyme was either
deactivated heating with EDTA or removed by the RNeasy Mini Kit Clean Up (Qiagen)
columns. RNA was converted into cDNA using reverse transcriptase enzyme (Maxima
First Strand cDNA synthesis for qRT-PCR, Thermo Fisher Scientific) and cDNA
template was diluted 1:5 with DEPC-treated water, then further diluted with 4X Yellow
Sample Buffer for use with DyNAmo Flash SYBR Green qPCR reagent (Thermo
Fisher). A PCR master mix was prepared by combining 2X Master mix, the appropriate
forward or reverse primers (stock concentration 10 μM or 10X), and DEPC-treated
water. 1 μL of diluted cDNA template was added to 4 μL of PCR master mix in individual
wells of a 384-well clear PCR reaction plate (Thermo Fisher). Samples were run in
triplicate and included no reverse transcriptase (NRT) and no template controls (NTC).
The intercalated SYBR Green was measured with a BioRad CFX284TM Real-time PCR
detection system. Data was analyzed using delta cycle threshold (∆Ct) and delta-delta
Ct (∆∆Ct) derivations by comparing target gene expression to relative expression of the
endogenous housekeeping genes GAPDH or HPRT. Melt curve analysis was used to
evaluate gene specific amplification versus primer dimerization or nonspecific
amplification. A list of the primers and their sequences is found in Table 1.
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2.4 Protein analysis
Cellular protein was isolated by freeze thaw method: cells were washed once
with cold PBS, detached by scraping, and pelleted by centrifugation before adding
freeze-thaw lysis buffer containing 600 mM KCl, 20 mM Tris-Cl (pH 7.8), 20% glycerol,
and 1x each of protease and phosphatase inhibitor (EMD Chemicals Inc., San Diego,
CA). Samples were submerged in liquid nitrogen for 5 minutes and thawed on ice for 5
minutes three times. Cellular debris was removed by centrifuging at 13,200 x g for 5
minutes. BCA protein analysis (Pierce Biotechnology, Rockford, IL) was performed on
the supernatant to measure the protein concentration.
2.5 Western blot analysis
Cell lysates collected by freeze-thaw were separated based on size using SDSpolyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes.
Membranes were blocked in Tris-buffered saline (TBS; 0.05 M Tris-HCl and 0.2 M NaCl,
pH 7.4) containing 0.1% (v/v) Tween-20 (TBST) and 5% non-fat milk (w/v) for 1 hour at
room temperature then probed with the appropriate primary antibody. Primary
antibodies used included mouse anti-human IDO (RayBiotech, Norcross, GA, USA) and
mouse anti-human beta-actin (Sigma-Aldrich, St Louis, MO, USA). Each antibody was
diluted in TBST containing 5% non-fat milk and used separately to avoid cross-reactivity
or issues with their target protein sizes being similar. Probing was performed overnight
at 4ºC. After rinsing the membranes were incubated with HRP-conjugated anti-mouse
IgG for 1 hour at room temperature, and then rinsed again. Bands were visualized using
the West Pico and West Femto (Pierce Biotechnology) and the ChemiDoc XRS+
Imaging System (Bio-Rad Laboratories, Hercules, CA, USA). Protein size was

15

determined by comparison with a biotinylated protein ladder (Cell Signaling Technology
Inc., Danvers, MA) and the density of each band was quantified with ImageJ image
analysis software [93] following a method detailed by Miller [94]. Results are reported as
the relative abundance: a ratio of the density of the IDO band to the beta-actin band.
2.6 Enzyme-linked immunosorbant assay (ELISA) analysis
Conditioned media from MSCs infected with 1 MOI of RSV as previously
described was clarified by centrifugation and the concentration of the immune regulator
prostaglandin E2 (PGE2) was measured by ELISA (R&D Systems, Minneapolis, MN,
USA). For IDO: Cell lysates were obtained by freeze-thaw as described previously and
diluted for use in the ELISA kit for IDO (Cloud-Clone Corp., Houston, TX, USA). Each
procedure was done in replicate and results shown were representative of repeated
experiments.
2.7 Tryptophan catabolism assay
To assess the activity of IDO we performed a tryptophan catabolism assay.
Protein from freeze-thaw lysates from MSCs were collected as described above and
treated with buffer containing 100mM PBS, 40mM ascorbate, 20uM methylene blue,
200ug/ml catalase, and 800uM L-tryptophan (pH 6.5). After a 30-minute incubation at
37ºC the chemical reaction was stopped with 30% trichloroacetic acid and heating to
52C for 30 minutes. Precipitate was removed and kynurenine in the supernatant was
detected with Ehrlich’s reagent (0.8% p-dimethylaminobenzaldehyde in acetic acid) by
reading absorbance at 490nm. Results are expressed as units per μg lysate where 1
unit of IDO activity is defined as the amount of enzyme producing 1nmol per hour of
kynurenine.
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2.8 Mitogen stimulation assay
To examine the effect of RSV infection on MSC regulation of lymphocyte
responses peripheral blood mononuclear cells (PBMCs) were isolated from fresh buffy
coats (Florida Blood Services, St. Petersburg, FL, USA) by centrifugation in FicollPaque PLUS (Amersham Pharmacia Biosciences, Uppsala, Sweden), counted, and
labeled with carboxyfluorescein succinimidyl ester (CellTrace CFSE, Life Technologies).
Stained cells were cultured in RPMI containing 10% FBS and 1% antibiotic and
stimulated with the plant-derived T cell mitogen phytohemagglutinin (PHA) in the
presence of MSCs or conditioned media from MSCs infected 48hrs prior. Proliferation of
lymphocytes was assessed by flow cytometry 5 days later using an LSRII flow
cytometer (BD Biosciences, San Jose, CA, USA). Results were analyzed using FlowJo
software (Treestar, Ashland, OR, USA).
2.9 IDO activity, IFN-β signaling, RIG-I and endosomal TLR-pathway inhibitors
In order to investigate the contribution of IDO to the inhibition of PBMC
proliferation human MSCs were infected with RSV as previously described. After
removing infection media MSCs were incubated in complete MSC media containing the
IDO-inhibitor 1-methyltryptophan (1-MT, Santa Cruz Biotechnology) at 1mM. After 48
hours supernatants clarified by centrifugation were used in the PBMC proliferation
assay as previously described. An alternative IDO inhibitor, vitamin K3 (menadione,
Sigma-Aldrich, St Louis, MO, USA) [95] was used at 10μM to confirm the 1-MT results.
Additionally, to interrogate the pathways leading to IDO expression we treated
RSV infected MSCs with either the endosomal TLR inhibitor chloroquine (10μg per mL,
Sigma-Aldrich), the RIG-I pathway inhibitor BX795 (1μM, Invivogen, San Diego, CA,
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USA) or a neutralizing antibody to IFN-β (IFNb/A1, 10μg per mL, BioLegend, San
Diego, CA, USA). Additionally the TLR3-specific inhibitor, TLR3-dsRNA Complex
inhibitor (Calbiochem, San Diego, CA, USA) was used to interrogate that signaling
pathway [96] at a 50 μM final concentration. The inhibitory oligonucleotide (iODN) ODN
2088 (Innaxon, Tewkesbury, UK) was also used as a specific inhibitor to the TLR7, 8,
and 9 pathways at a concentration of 50 μg per mL [97].
2.10 Mouse strains and methods
Wild type Balb/c and C57Bl/6 mice (WT) as well as B6.129-Ido1tm1Alm/J mice
deficient in IDO (IDO-KO) were purchased from Jackson Laboratories. Mice were
infected with RSV when they were 6-8 weeks old by intranasal administration under
light anesthesia via inhaled isoflurane. Five days post infection the mice were
euthanized and lungs were collected for histology, RNA, and PFU quantification as
follows: The right bronchus was clamped shut while the left lung was perfused with 4%
paraformaldehyde (PFA) in PBS via the trachea, then removed to a vial containing 4%
PFA for histology. The right lobes were removed, minced, portioned into two 1.5 mL
tubes, and snap-frozen on dry ice for RNA and plaque forming unit assays.
All animal procedures were reviewed and approved by the University of South
Florida’s Institutional Animal Care and Use Committee and the VA Subcommittee on
Research Safety, Animal Component of Research Protocol.
2.11 Mouse lung histology
After fixing overnight the lungs for histology were cryopreserved in 15% and then
30% sucrose before embedding in Tissue-Tek OCT medium (VWR, Radnor, PA, USA)
and freezing on dry ice. Five-micron sections were mounted on slides using a
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cryomicrotome, dried in a humidified chamber and washed with PBS to remove
embedding media. Then the sections were either directly stained with hemaxotoxylineosin (HE) staining or steamed at 95ºC in unmasking solution (Vector Laboratories) for
immunohistology. Sections were permeabilized with methanol and blocked for 30
minutes with 5% bovine serum albumin (BSA) diluted in Tris-buffered saline containing
0.1% Tween-20 (TBST). The primary goat anti-RSV (Millipore, Ab1128) was diluted in
2.5% BSA in TBST and added to sections for overnight incubation at 4°C. Sections
were washed and the secondary donkey anti-goat conjugated to Alexa Fluor 555 was
similarly diluted and added to the tissue overnight, followed by washing and
counterstaining with DAPI-containing anti-fade media (Vector Laboratories) and
mounted with a coverslip for imaging. Fluorescent images were captured using an
Olympus BX51 microscope with DP72 digital camera.
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Table 1. Real-time RT-PCR primers for human and RSV genes
Gene

Ref Seq

Primer

Sequence (5'-3')

Amplicon

Exon Location

GAPDH

NM 002046.3

IDT 103685527

CCACATCGCTCAGACACCAT

87

2 to 3

IDT 103685147

AAAAGCAGCCCTGGTGACC

IDT 103685155

CATCTAGCAAATACACCATCCA

70

N/A

IDT 103686014

TTCTGCACATCATAATTAGGAGTATCAA

IDT Hs.PT.51.20299051

AGGAGCACTTCATCTGTTTAGG

140

1 to 4

184

3 to 4

144

1 to 1

89

1 to 2

94

1 to 1

136

1 to 1

113

3 to 4

RSVN

IL1B

M74568.1

NM 000576

GCCAATCTTCATTGCTCAAGTG
IL-6

IL8

NM 000600.3

NM 000584

IDT 103685150

GATGGCTGAAAAAGATGGATGC

IDT 103705045

CTGCAGGAACTGGATCAGGACT

IDT Hs.PT.51.755000.g

ACACAGAGCTGCAGAAATCAG
TTTCAGAGACAGCAGAGCAC

CXCL12

NM 000609

IDT Hs.PT.51.2268843

CATCTGTAGCTCAGGCTGAC
ATGAACGCCAAGGTCGTG

IFNA2

NM 000605

IDT Hs.PT.53a.24294810.g

TTGACTTGCAGCTGAGCA
CCCATTTCAACCAGTCTAGCA

IFNB

NM 002176

IDT Hs.PT.53a.28162302.g

GTCAAAGTTCATCCTGTCCTTG
CTCCACTACAGCTCTTTCCAT

IFNG

NM 000619

IDT Hs.PT.53a.2672945

CGACAGTTCAGCCATCACTT
GCAACAAAAAGAAACGAGATGAC
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Table 1. (Continued)
Gene

Ref Seq

Primer

Sequence (5'-3')

Amplicon

Exon Location

IL1RN

NM 000577

IDT.Hs.PT.51.4381999

TTGTCCTGCTTTCTGTTCTCG

89

7 to 8

125

4 to 6

99

1 to 2

109

5 to 5

115

1 to 2

93

1 to 4

256

3 to 3

CTGTCCTGTGTCAAGTCTGG
IDO1

NM 002164

IDT Hs.PT.51.3356559

ACGTCCATGTTCTCATAAGTCAG
GTTCCTTACTGCCAACTCTCC

NOS2

NM 000625

IDT Hs.PT.51.22593297

GAGCTCAGATGTTCTTCACTGT
AAGTTCTCAAGGCACAGGTC

CX3CR1

NM 001171174 IDT Hs.PT.53a.27377849.g

CAGGTTCAGGAGGTAAATGTCG
CTACTCCGTCATCTTTGCCAT

CXCR4

NM 003467

IDT Hs.PT.51.22298491

CCTCGGTGTAGTTATCTGAAGTG
AGCAGGTAGCAAGTGACG

CXCR2

NM 001168298 IDT Hs.PT.51.309915

CTGTGACCTGCTGTTATTGGA
GTACAGTGCTATTCTGCCTAGA

TLR3

NM 003265.2

IDT 143665195

TTGCTCATTCTCCCTTACAC

IDT 143665196

CTTCGGAGCATCAGTCGT
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Table 2. Real-time RT-PCR primers for mouse genes
Gene

Ref Seq

Primer

Sequence (5'-3')

Amplicon

Exon Location

mGAPDH

NM 008084

IDT Mm.PT.39a.1

GTGGAGTCATACTGGAACATGTAG

150

2 to 3

119

1 to 1

127

1 to 2

127

15 to 16

AATGGTGAAGGTCGGTGTG
mIFNB1

NM 010510.1

IDT Mm.PT.56a.30132453.g

GGCATCAACTGACAGGTCTT
ACTCATGAAGTACAACAGCTACG

mIDO1

NM 008324

IDT Mm.PT.58.42364388

AAGCTGCCCGTTCTCAATC
AGACCACCACATAGATGAAGATG

mNOS2

NM 001313922

IDT 134627193

CCAAGCCCTCACCTACTTCC

IDT 134627194

CTCTGAGGGCTGACACAAGG
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Chapter 3: Respiratory Syncytial Virus Infection of Human
Mesenchymal Stem Cells

3.1 Introduction
The finding that MSCs could also be target for RSV infection [76] suggested two
important possibilities: that perhaps a stromal cell type in the lung or nasal mucosa
could be an extra-epithelial target and reservoir for the virus and that the infection of
these potent immune regulatory cells could contribute to RSV-mediated regulation of
the immune system. Building on the work of Rezaee et al. (2011) [76] we first sought to
characterize the infection of human mesenchymal stem cells (MSCs). We did this by
infecting several different lines of both umbilical cord blood-derived and bone marrowderived MSCs. Multiple lines of these cells were purchased either from Vitrobiopharma
(umbilical cord blood-derived MSCs) or Texas A&M (bone marrow-derived MSCs).
Infection was confirmed by fluorescent microscopy and measuring viral RNA products
by reverse transcriptase real-time PCR. RSV plaque forming units were quantified from
cell culture supernatant to measure the productivity of the infection.
The results of this work confirmed that RSV productively infects human MSCs
and that the infection can extend over 10 days, producing RSV transcripts detected by
RTqPCR, protein products detected by antibody staining, as well as infective virions
quantified by PFU assay.
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3.2 RSV infects human MSCs
Human MSCs were infected with rA2-KL19F at 1 MOI and fixed with 4% PFA at
24, 48, and 72 hours post-infection. Fluorescent micrographs were captured to visualize
RSV infected cells based on their mKate2 expression (red fluorescence) as well as all
cells by nuclear staining with DAPI (blue) (Figure 1a). ImageJ analysis was performed
using the cell counter plug-in to quantify the cells as well as the cells positive for RSV
infection in each field (10 per well, 3 wells per time point, 4 human MSC lines) (Figure
1b). Results showed that RSV infected 19% ± 4% cells were infected at 24 hours post
infection, 72% ± 7% at 48 hours, and 81% ± 10% of MSCs were infected at 72 hours
post infection (mean ± SD).
As an alternative approach to confirm infection in MSCs cells were plated at 3 x
105 cells per well in a 6 well plate with a sterilized collagen-coated 25mm round
coverslip in the well. After 24 hours the MSCs were infected with RSV at 1 MOI in OptiMEM with 2% FBS or mock infection media for 90 minutes at 37C. The infection media
was then aspirated and the wells were incubated with complete MSC media for 48 or 72
hours. Media was aspirated and the cells were washed with PBS. Then the coverslip
was removed and fixed in cold acetone before staining for RSV with an anti-RSV
antibody conjugated to the fluorescent molecule FITC and containing the cytoplasmic
stain Evan’s Blue which fluoresces red (#5022 Mouse anti-RSV+FITC monoclonal kit;
Millipore, Billerica, MA, USA). The stained coverslip was washed with PBS and
mounted on a slide upside down with mounting media containing 4,6-diamidino-2phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA). The results showed
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specific staining of MSCs only on the RSV infected coverslips, confirming the result
found using the red fluorescence-expressing virus (Figure 3).
3.3 Duration of RSV infection in human MSCs
To evaluate the duration of infection an experiment was designed utilizing the
fluorescence of virally infected cells and a plate reader. Human MSCs were grown in a
96-well plate and infected with 0.01, 0.1, or 1.0 MOI rA2-KL19F, UV-inactivated RSV, or
mock infection media with 8 replicates of each treatment group. Cells were grown for 12
days with media being refreshed every 3 days. Mean fluorescence intensity at excitation
588 nm and emission 633 nm was assayed using the Synergy H4 Hybrid Multi-Mode
Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA) (Figure 2). Results
showed an extended infection in MSCs even at 1 infective unit per cell, peaking from 2
to 4 days before fluorescence diminished. Cells infected with 0.01 MOI or 1 infective
unit per 100 cells had a slower and longer infection, peaking at 6 day to 9 days.
Interestingly, in the RSV-infected groups some human MSCs remained even after red
fluorescence intensity returned to mock and UV-inactivated levels, indicating that
perhaps some resistant cells grew out or the virus infection was self-limiting, or perhaps
became abortive or latent at some point in time. As a note: the UV-inactivated virus was
used at all the same MOIs as the active virus, however the results for each MOI of
inactivated virus were similar and for simplicity and readability of the figure only the
highest MOI was shown. This result is consistent with some other long-term RSV
infection studies in other cells types such as dendritic cells, macrophages or HEP-2
cells which have been reported to support prolonged persistent infections [70, 98-101].
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3.4 Plaque forming unit and viral transcript quantification
To evaluate whether the productivity of RSV infection in human MSCs the culture
supernatants from infected cells or mock-infected cells were collected and plaque
forming unit assay was performed as described previously. Briefly, HEP-2 cells were
infected with varying dilutions of supernatant for 90 minutes rocking at regular intervals.
Infection media was removed and warmed growth media containing 5% methylcellulose
was added. The principle of the assay is to limit the viral spread to just the neighboring
cells allowing the detection of individual infective units. Results from this assay show
that RSV replicates in human MSCs and produces infective virions that are released
from the cells into the culture supernatant (Figure 4a).
Additionally, expression of the RSV specific transcript for the RSVN gene was
measured in human MSCs. Briefly, MSCs were infected as previously described for 6,
12, 24, or 72 hours prior to collection of total RNA using the TRIzol method. RNA was
purified and cleaned using a DNase I treatment (Roche) as well as an RNA cleanup
step (RNeasy Mini Kit, Qiagen). After reverse transcription of the mRNA to cDNA the
expression of RSVN was measured using predesigned primers (Integrated DNA
Technologies). Gene expression was normalized to the cellular housekeeping gene
GAPDH and results were reported as expression relative to uninfected cells (Figure 4b).
Statistical analysis confirmed that RSVN was detectable in the infected MSCs at all time
points, increasing from 6 to 72 hours post infection. These results, in concert with those
reported above, confirm the viral infectivity and productivity of MSCs with respect to
RSV and reveal the potential for in vivo infection of this important regulatory cell type in
natural infection.
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A.

Figure 1. RSV infection of human MSCs (Continued on next page)
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B.

Figure 1. RSV infection of human MSCs (Continued)
Four lines of human MSCs infected for 24, 48, or 72 hours with 1 MOI of
virus were captured with a fluorescent microscope for mKate2 (red) expressing cells as
well as DAPI (blue) stained cells (A). Percentage of cells infected reported as red cells
divided by total nuclei, quantified by ImageJ analysis (B). The mean percent infected is
shown with the error bars representing the standard deviation, n = 4.
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Figure 2. Duration of RSV infection in human MSCs
The mean fluorescent intensity of infected MSCs at excitation/emission of
588/633 nm was assessed over 12 days. Results reported as MFI normalized to the
fluorescent intensity detected in the mock-infected group. Each group had an n = 8 and
error bars represent the standard deviation.
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Figure 3. Staining of infected MSCs with a RSV-specific antibody
Human MSCs grown on coverslips, infected with 1 MOI of RSV, and
immunostained at 48 or 72 hours post-infection with a monoclonal antibody to RSV
tagged with FITC (green), Evan’s blue dye (red) and DAPI (blue). Total magnification of
images is 200X (inset 1000X) and scale bar is 50μm. Results characteristic of multiple
experiments and fields of view.
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Figure 4. Plaque forming unit assay and quantification of RSVN transcript in
infected MSCs
Infective virions collected from cell culture supernatants were detected and
quantified by PFU assay in HEP-2 cells by serial dilution and indicated that RSV
infected MSCs are capable of producing infective viral progeny (A). RSVN transcripts
detected in MSCs at 6, 12, 24 and 72 hours post infection normalized to mock (B).
Results representative of multiple experiments, each done with 3 replicates per group,
error bars represent SD. * p < 0.05, ** p < 0.01, *** p < 0.001
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Chapter 4: Cytokine and chemokine response of RSV-infected MSCs

4.1 Introduction
The immune system coordinates a response to RSV infections via the production
and secretion of a number of bioactive signaling molecules called cytokines and
chemokines. Proinflammatory cytokine activity can leads to increased blood circulation
and immune cell infiltration. This immune cell signaling manifests as the symptoms
experienced by infected patients; fever, inflammation, mucus hyper-secretion, and
obstruction of the airways. Many proinflammatory cytokines have been shown to
increase in the airway during RSV infection, including interleukin (IL)-6, IL-1β, IL-8 (or
CXCL8), tumor necrosis factor (TNF) α, RANTES (regulated on activation normal T cell
expressed and secreted, or CCL5), macrophage inflammatory protein (MIP)-1α, MIP-1β
(or CCL4), eotaxin, and a host of others [102-106]. These cytokines, and others such as
like IL-1α and IL-33, are secreted upon stimulation of pathogen recognition receptors
(PRRs) by viral factors [107] and result in infiltration, inflamation, and mucus hypersecretion as well as tissue remodeling in the airway.
Interestingly, mouse models have shown that the cytokine profile may depend on
the viral strain or even a single protein. For example, reports indicate that murine
lymphocytes treated with the RSV envelope G protein of RSV were stimulated in vitro
and released Th2-like cytokines [108] while the envelope F protein stimulated Th1-
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promoting cytokines [109, 110]. Even different strains of the virus, such as the lab strain
A2 and clinical isolates have been found to have varying cytokine responses [21, 111115] and changing a single protein can have dramatic effects on the manifestation of
RSV induced disease [116]. Additionally, age of infection has also been found to
influence cytokine profile and infection duration [21, 106]. It is possible that different
individual outcomes to RSV infections, such as more severe disease or recurrent
wheeze later in life, could be due to this diverse response to viral components.
The aim of the following experiments was to evaluate the cytokine response of
human MSCs after RSV infection. A panel of important inflammatory, viral response,
and immune regulatory factors were assayed for expression by reverse transcription
qPCR . This response was compared with that seen in the traditional target cell type for
RSV, normal human bronchial epithelial (NHBE) cells.
4.2 RSV induction of inflammatory cytokine and chemokine expression
To investigate the cytokine responses to RSV infection in human MSCs total
RNA was isolated after 72 hours of infection, reverse transcribed to cDNA, and used in
a qPCR reaction as previously described. Results indicated that unlike NHBE cells,
which expressed increased the proinflammatory cytokines IL-6 (4.6-fold, p = 0.0220)
and stromal cell-derived factor (SDF)-1 (or CXCL12, 2-fold, p = 0.0457), RSV-infected
MSCs expressed more IL-8 (or CXCL8, 2.85-fold, p = 0.0291) than mock-infected cells
(Figure 5). Additionally, the antiviral response factors IFN-α, IFN-β, and IFN-γ were
examined after RSV infection. An increase in IFN-β transcripts was observed for both
RSV infected NHBE cells (2.41-fold, p = 0.0334) and MSCs (106.9-fold, p = 0.0036)
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compared to mock but no change in either IFN-α or IFN-γ were found in either cell type
(Figure 6).
Also, receptors for selected chemokines were also assayed for expression after
infection with RSV by RTqPCR; CX3CR1 (fractalkine receptor), CXCR2 (IL-8 receptor,
beta), and CXCR4 (or fusin, the receptor for SDF-1). Interestingly, while infected NHBE
cells did not show any increase in transcripts for the receptors measured RSV-infected
MSCs showed a 5.2-fold increase in CXCR4 expression compared with mock (p =
0.0085) (Figure 7).
4.3 Immune regulatory factor expression during RSV infection
RSV-infected NHBE cells and MSCs were tested for expression of the immune
regulatory factors IL-1 receptor antagonist (IL-1ra), inducible nitric oxide synthase
(iNOS) and IDO (Figure 8a). RSV infection increased IDO transcripts 68.9-fold
compared to mock infected (p=0.0023) in MSCs. A significant but less dramatic 5.9-fold
increase was also observed for in RSV infected NHBE cells (p=0.0120). No changes in
IL-1ra or iNOS were seen at 72 hours post infection. As another potential immune
regulatory pathway, prostaglandin E2 (PGE2) level was measured by ELISA (Figure 8b).
RSV-infection was not associated with any change in PGE2 levels in MSC culture
supernatant.
4.4 Dynamics of cytokine and immune regulatory factor expression throughout
the infection
While the previous results provided a list of important cytokines, receptors, and
immune regulators during RSV infection of MSCs the next step was to investigate the
expression of these genes over the course of the infection. Human MSCs were infected
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with RSV and RNA was collected from these cells as previously described at 5 times
points; 6, 12, 24, 48, and 72 hours post infection. Results showed a steady increase of
IFN-β expression from 6 to 72 hours during RSV infection, with the increase achieving
significance at 12, 24, 48, and 72 hours versus mock (Figure 9a); 7.9-fold at 12 hours (p
= 0.009), 65.7-fold at 24 hours (p = 0.004), 78.5-fold at 48 hours (p = 0.045), and 110.9fold at 72 hours post infection (p < 0.001). Conversely, IFN-γ did not show any
significant change in expression compared with mock-infected MSCs at any of the time
points tested (Figure 9b). The expression of IDO transcripts were slightly delayed
compared with IFN-β, only reaching significance at 24, 48, and 72 hours post infection
(Figure 9c); 15.9-fold at 24 (p = 0.03), 108.3-fold at 48 (p < 0.001), and 70.2-fold at 72
hours post infection (p < 0.001). In contrast to IFN-β and IDO expression the levels of
CXCR4 transcripts followed a cyclical pattern, elevated compared to mock at 6 (3.4-fold,
p = 0.06), 24 (4.5-fold, p = 0.047), and 72 hours post infection (5.2-fold, p = 0.0029)
while dropping back to quantities similar to mock-infection when measured at 12 and 48
hours post infection (Figure 9d).
4.5 Indoleamine-2,3-dioxygenase activity in RSV infected MSCs
As a potent immune regulator IDO expression in RSV-infected MSCs was of particular
interest. Therefore, Western blot analysis was performed on protein collected by freezethaw from infected or mock-infected MSCs at 24 and 48 hours post infection, as
previously described. The results confirmed the presence of IDO protein in MSCs at
both time points (Figure 10a). At 24 and 48 hours RSV-infected MSCs showed a 0.54
and 0.12 relative abundance to beta actin respectively while mock-infected MSC lysates
showed 0.08 and 0.06 relative protein abundance at the same time points; a 6- and 2-
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fold increase at 24 and 48 hours due to RSV infection. The gold standard in assaying
enzymes is to measure their activity, therefore a tryptophan catabolism assay was
performed using the lysates from infected and mock MSCs at 24 and 48 hours post
infection (Figure 10b). Briefly, freeze-thaw lysates from RSV-infected MSCs were
treated with tryptophan catabolism buffer for 30 minutes at 37ºC before stopping the
reaction and measuring kynurenine in the supernatant with Ehrlich’s reagent. The
results are expressed as IDO units per μg lysate where 1 unit of IDO activity is defined
as the amount of enzyme producing 1 nanomole of kynurenine per hour. IDO activity
was detected in RSV-infected MSCs at 24 and 48 hours while no activity was detected
in mock-infected MSCs.
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Figure 5. Cytokine expression in MSCs following RSV infection differs from NHBE
cells
Cytokine transcription in RSV-infected NHBE cells and MSCs after 72 hours post
infection by RTqPCR reported as fold expression compared to mock-infected NHBE
and MSCs. Infected NHBE had higher IL-6 and SDF-1 transcripts while infected MSCs
had increased IL-8 expression. The dashed line shows expression in mock treated cells
and error bars represent the standard error of the mean (SEM); Statistical analysis by 2way ANOVA, n = 6 for both cell types and treatments. * p < 0.05 vs. mock
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Figure 6. RSV infection increases IFN-β transcription in human MSCs and NHBE
cells
Interferon transcript expression in RSV-infected NHBE and MSCs compared to
mock-infected cells. IFN-β expression was increased in both NHBE (2.409-fold, p =
0.0334) and MSCs (106.9-fold, p = 0.0036) compared with mock-infection. The dashed
line shows expression in mock treated cells and error bars represent the standard error
of the mean (SEM); Statistical analysis by 2-way ANOVA, n = 6 for both cell types and
treatments. * p < 0.05, ** p < 0.01 vs. mock
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Figure 7. Chemokine receptor CXCR4 expression increased in MSCs after RSV
infection
Selected chemokine receptor transcription in RSV-infected NHBE cells and
MSCs after 72 hours post infection by RTqPCR reported as fold expression compared
to mock-infected NHBE and MSCs. RSV-infected MSCs showed a 5.2-fold increase in
CXCR4 expression compared with mock (p = 0.0085). NHBE cells did not show any
increase in transcripts for the receptors measured. The dashed line shows expression in
mock treated cells and error bars represent the standard error of the mean (SEM);
Statistical analysis by 2-way ANOVA, n = 6 for both cell types and treatments. ** p <
0.01 vs. mock
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Figure 8. Immune regulatory factor expression during RSV infection
The expression of IL-1Ra, IDO and iNOS were examined in RSV- or mockinfected NHBE cells and MSCs after 72 hours post infection by RTqPCR, reported as
fold expression compared to mock. The expression of IDO in both NHBE cells and
MSCs was increased after infection with RSV while transcripts of IL-1 receptor
antagonist and iNOS were not different from mock (A). PGE2 expression was assessed
by ELISA and showed no change in RSV- versus mock-infected MSCs (B). * p < 0.05,
** p < 0.01
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(Continued on next page)
41

Figure 9. Temporal dynamics of RSV-induced transcripts in human MSCs
(Continued)
Human MSCs were infected with RSV and RNA was collected from these cells
as previously described at 5 times points; 6, 12, 24, 48, and 72 hours post infection.
Transcripts from RSV-infected human MSCs revealed a steady increase in IFN-β from 6
to 72 hours post infection (A). IFN-γ expression was not significantly changed in RSVinfected compared with mock-infected MSCs at any of the time points (B). The change
in expression of IDO transcripts reached significance at 24, 48, and 72 hours post
infection (C). The levels of CXCR4 transcripts followed a cyclical pattern, higher
compared to mock at 6, 24, and 72 hours post infection and at mock-infection levels 12
and 48 hours post infection (D). RSVN transcript was measured and showed a steady
increase in viral transcripts consistent with a productive infection (E). Results shown are
typical of replicated experiments. n = 3 for 6, 12, and 24 hours, n = 6 for 48 and 72 hour
time points. * p < 0.05, ** p < 0.01, *** p < 0.001
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Figure 10. Western blot and enzymatic activity of IDO in infected MSCs
The presence of IDO protein in RSV-infected MSCs was confirmed by Western
blot (A). Activity of the enzyme was measured using MSC lysates at 0, 24 and 48 hours
after infection by tryptophan catabolism assay and indicated active IDO following RSV
infection (B).

43

Chapter 5: Role of Mesenchymal Stem Cells in Respiratory Syncytial
Virus Immune Regulation by Indoleamine-2,3-dioxygenase

5.1 Introduction
Indoleanime-2,3-dioxygenase (IDO) was first described in 1963 [117, 118] as an
alternative enzyme to typrtophan-2,3-dioxygenase (TDO) in the oxidative catabolism of
tryptophan [119]. These enzymes catalyze the conversion of tryptophan to formylkynurenine. TDO and IDO are members of a small family of heme-containing enzymes,
and while TDO is found in both prokaryotes and eukaryotes IDO has only been
identified in eukaryotes [120, 121]. There are two IDO genes in eukaryotes, IDO1 and
IDO2. IDO2 appears to be the ancestral form, found in lower vertebrates, while IDO1 is
hypothesized to have arisen by gene duplication during tetrapod evolution [122].
Mammalian expression of TDO is limited to the liver, however IDO mRNA can be found
expressed in a diverse array of extra-hepatic cell types and tissues [123]. Interest in
IDO as a regulator of immune responses arose when its role in preventing maternal
rejection of the fetus was discovered [124].
Of the essential amino acids tryptophan is the most limited, and as a
consequence protein synthesis and therefore cell activity, growth, and division are all
dependent on the availability of tryptophan [125]. IDO activity has been shown to have
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an anti-proliferative function on cells that can be reversed by exogenous tryptophan
[126]. It has been estimated that 99% of tryptophan enters the IDO catabolism pathway
[127]. The catabolic activity of IDO and its protein level expression are highly regulated,
as activation of IDO can rapidly reduce tryptophan concentrations to nanomolar levels
[127, 128].
This tryptophan depletion presents a potential antimicrobial and antiviral strategy,
by imposing a condition of amino acid starvation on pathogens and limiting production
of viral products [129, 130]. In parasitic infection by Toxoplasma [131, 132] and
Trypanosoma cruzi [133] IDO expression has been found to be beneficial and limited
the growth of the parasites while conversely in Leishmania infections IDO induction in
infected dendritic cells is associated with immune escape by the parasite [134]. The
pathogenesis of some bacterial infections have been linked to IDO, such as
Mycobacterium leprae and tuberculosis (145) and streptococcal toxic shock-like
syndrome (143). Activation of IDO has also been linked to viral infections including
hepatitis C [135]. In studies of influenza IDO expression has been implicated in
reduction of memory B cells following primary infection, decreasing the secondary
immune response upon future infection [136-140]. Infections with human
immunodeficiency virus (HIV) has been shown to induce IDO, associated with both
reduced CD4+ T-cell activation and also the HIV-associated depression and weight loss
potentially due to depletion of tryptophan, the precursor to the neurotransmitter
serotonin [141]. Conversely, during herpes simplex viral infections IDO induction
appears to be beneficial and has been found to reduce viral replication [142].
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IDO activity has a wide range of immune modulatory effects [143], including
immunosuppression by limiting proliferation in CD4 and CD8 T cells as well as NK cells.
Additionally, tryptophan depletion as well as tryptophan metabolites have been
suggested to be involved in modulation of Th1 versus Th2 type responses [144, 145].
IDO activity induces apoptosis in proliferating T cells, preferentially in Th1 versus Th2
cells [146], potentially shifting the balance between the two responses. Antigen
presenting cells, such as macrophages, have been shown to have a specialized highly
efficient tryptophan-transport system which allows them to resist the tryptophan
starvation effects of IDO activity, while T cells have been shown to only use the
conventional tryptophan transport mechanism [128]. Immune regulation by IDO has
been considered one of several mechanisms for tumor immune escape, observed in a
number of cancer malignancies including colorectal cancer and T cell leukemia [147,
148].
In order to evaluate the effect of RSV infection on immune regulation by MSCs a
mitogen-stimulation assay with PBMCs either cultured or treated with conditioned media
from MSCs was used. Two IDO-specific inhibitors were utilized to investigate the role of
IDO in this process. Results implicated IDO as one of the factors produced by cells
following RSV infection that contributes to immune regulation by the virus.
5.2 Secreted factors from RSV-infected human MSCs regulate lymphocyte
proliferation
A mitogen proliferation assay was employed to investigate the effect that MSC
infection by RSV may have in immunity. Human PBMCs were isolated from fresh buffy
coats as previously described and stained with CFSE at 2.5 μM and grown with or
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without stimulation by PHA, a plant-derived mitogen. Several growth conditions were
assayed in order to evaluate the immune regulatory effects of human MSCs after RSV
infection: control cells not treated with MSCs or MSC conditioned media; PBMCs
cultured directly with MSCs; and PBMCs treated with conditioned media from MSC
cultures or fresh complete MSC media as a control (1:1 mix with RPMI-10). After 5 days
at 37ºC the PBMCs were collected and CFSE fluorescence was analyzed by flow
cytometry.
Results indicated that PBMCs treated with cell culture supernatant from infected
MSC cultures had significantly reduced proliferation compared to PHA control (29.4%
versus 76.9%, p < 0.0001) while those treated with media from uninfected MSCs were
not significantly affected (75.5% versus 76.9%, p = 0.5633) (Figure 11b). The human
PBMCs that were cultured directly with human MSCs showed no proliferation
regardless of whether the MSCs were infected with RSV or not; RSV-infected MSCs:
4.52% (p = 0.3885); mock-infected MSCs: 3.94% (p = 0.5633) (Figure 11c).
Next, to further analyze the effect of secreted factors from MSCs on human
PBMC proliferation we tried varying amounts of CM from MSCs. Results showed a
dose-dependent decrease in mitogen-stimulated proliferation of PBMCs treated with the
CM from either RSV- or mock-infected MSCs (Figure 12). As found previously, the cells
treated with CM from MSCs infected with RSV had significantly lower proliferation than
those treated with mock at all concentrations tested. PBMCs cultured with 25% CM from
RSV-MSCs showed 40% less proliferation than those cultured with CM from mockMSCs (46% vs. 86%, p = 0001). Similarly, PBMCs cultured with 50% or 75% CM
showed a reduction in PHA-stimulated proliferation, 37% less (37% vs. 74%, p <
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0.0001) and 15% less (18% vs. 33%, p = 0.0234), respectively. These results showed
that RSV infection increased the regulatory effect of MSCs via factors in the CM.
These results indicated that there was some factor or factors secreted by
infected MSCs that could down regulate the proliferation of PBMCs in response to a
mitogen. Based on the previous results we hypothesized that an IDO metabolite
kynurenine could be one of the factors involved. Based on the lowest p-value (i.e.
largest statistical difference) seen between infected and mock CM during the
concentration experiments we chose to perform the following experiments with 50%
MSC CM treatment.
5.3 IDO metabolite kynurenine plays a role in MSC-mediated immune regulation
In order to test out hypothesis that increased IDO production by RSV-infected
MSCs was responsible for modulating PBMC expansion we used the IDO activity
inhibitor 1-MT. This molecule acts as a competitive inhibitor, binding to the same site on
IDO as tryptophan. The human MSCs were infected as previously, however in the
treatment group the infection media was replaced with MSC media containing 1-MT at a
concentration of 1 mM. The rest of the experiment was performed as previously
described with PBMCs being treated with MSC CM or MSC media as a control, diluted
1:1 in RPMI-10. PBMCs treated with CM from RSV-infected MSCs showed a significant
reduction in mitogen-stimulated proliferation (38.77%) compared with mock (72.64%; P
< 0.0001) (Figure 13a). Treatment of MSCs with 1-MT during the RSV infection restored
the mitogen-stimulated proliferative capacity of PBMCs (66.27%; p < 0.0001 versus
RSV-MSC CM; not significantly different from mock-infected MSCs, p = 0.17). Similar
results were found when MSCs were treated with the alternative IDO activity inhibitor
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vitamin K3 (71.40%; versus mock CM p = 0.7771, versus RSV-MSC CM p < 0.0001). To
demonstrate that this reversal on immune regulation by infected MSCs was not due to
inhibition of viral replication by these IDO inhibitors flow cytometry, RTqPCR, and
plaque assay were performed (note: vitamin K3 caused auto-fluorescence in mockinfected MSCs and was excluded from the FACS analysis). These showed that the
inhibitors had no effect on RSV infection or productivity (Figure 13b and c). Kynurenine
concentrations in the supernatants of MSC cultures were measured with Ehrlich’s
reagent following the second half of the tryptophan catabolism assay described
previously. Results showed that media from infected MSCs treated with the IDO
inhibitors had a lower kynurenine concentration than untreated cells (Figure 13d).
Taken together, these results demonstrate the potential immune regulatory role
of IDO production by MSCs in RSV infection, an effect that was reversed in the
presence of either of the IDO inhibitors. To understand this result better the next step
was to determine the mechanism behind the observed RSV-induction of IDO and
subsequent inhibition of PBMC proliferative capacity.
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Figure 11. Conditioned media versus co-culture treatment of PBMCs with RSVinfected human MSCs (Continued)
RSV or mock-infected human MSCs were used to treat PBMCs prior to mitogen
stimulation with PHA and proliferation assay measured by CFSE fluorescence. Three
replicates were performed for each treatment and histograms of representative FACS
reports are shown for each group and the mean of each group inlayed on the graph.
Control PBMCs were not treated with MSC cell culture supernatant and averaged
76.9% dividing cells (A). PBMCs treated with cell culture supernatant from infected MSC
cultures had significantly lower proliferation compared to PHA control (p < 0.0001) while
those treated with media from uninfected MSCs were not significantly affected (p =
0.5633); 29.4% and 75.5% dividing PBMCs respectively (B). PBMCs cultured directly
with human MSCs infected or not infected with RSV showed no proliferation with 4.52%
and 3.94% of cells dividing, not significantly different from PBMCs not receiving mitogen
stimulation (p = 0.3885 and 0.5633) (C). A graph summarizing the data; bars show the
mean and error bars represent the standard deviation (D). **** p < 0.0001 vs. PHA
control, † no significant difference vs. unstimulated control
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Figure 12. Conditioned media from RSV-infected MSCs reduces PBMC
proliferation in a dose-dependent manner
Freshly isolated PBMCs stained with CFSE, treated with either RSV or mock
conditioned media, and grown in triplicates with (line) or without PHA (shaded) for 5
days. CFSE fluorescence was measured by flow cytometry as an indication of
proliferation; representative histograms from the 50% CM treated groups are shown (A).
The proliferation of PBMCs treated with conditioned media from RSV-infected MSC was
reduced in a dose-dependent manner (B). Result of a representative experiment is
shown. Groups compared by one-way ANOVA with Fisher’s LSD test, error bars
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represent standard error of the mean (SEM), n = 3. * p < 0.05, *** p < 0.001, **** p <
0.0001 vs. mock MSC CM treatment
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Figure 13. Indoleamine-2,3-dioxygenase inhibitors block infected MSC regulation
of PBMCs
Freshly isolated PBMCs stained with CFSE, treated CM from MSCs, and
cultured for 5 days with the mitogen PHA. Flow cytometry for CFSE fluorescence as a
measurement of PBMC proliferation showed that 1-MT and vitamin K3 treatment during
infection of MSCs returned PBMC proliferation to mock levels (A). This effect was not
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due to a reduction in RSV infection shown by flow cytometry (B), PFU assay, and RSVN
expression (C). The concentration of kynurenine in the supernatants of infected MSCs
treated with the IDO inhibitors was lower than untreated cells (D). Significance between
groups determined by one-way ANOVA with Fisher’s LSD test. Results representative
of duplicate experiments, error bars represent SEM, n = 3. **** p < 0.0001
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Chapter 6: Mechanism of RSV-mediated Indoleanime-2,3-dioxygenase
Induction in Mesenchymal Stem Cells

6.1 Introduction
Several pathways of IDO induction have been identified. IDO can be induced by
addition of type I or type II interferons, microbial components such as LPS or dsRNA,
prostaglandins, and soluble forms of the immune regulatory receptor cytotoxic T
lymphocytes-associated antigen 4 (CTLA-4) [149, 150]. This distinguishes IDO from the
other major tryptophan catabolism enzyme TDO, which does not appear to be inducible
immunologically [128]. Negative regulation of IDO has been demonstrated in monocytes
by IL-4 [151] and in fibroblast by TGF-β [152].
While the major pathway of IDO induction in MSCs appears to be through IFN-γ
signaling there are many studies demonstrating IFN-γ-independent pathways; IL-18 and
IL-12 [153], and IFN-β [154, 155]. Also, HIV has been found to induce IDO activity in an
interferon-independent fashion [156]. A recently described IFN-γ-independent pathway
resulting the production of IDO involves IFN-β [154, 155]. In contrast to IDO stimulated
by IFN-γ, which functions as an immune regulator through its enzymatic catabolism of
tryptophan, IFN-β-induced IDO has been shown to act as a signaling molecule, which
when phosphorylated at its two immunoreceptor tyrosine-based inhibitory motifs
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(ITIMs), can lead to RelB/p52-mediated activation of the NF-κB pathway, and promote
IFN-β and TGF-β expression [157].
The lack of IFN-γ expression in MSCs and NHBE cells during RSV infection
coupled with the results presented previously of high IFN-β expression led to the
investigation of this signaling pathway as a potential mechanism of IDO induction.
Results from this study demonstrated the importance of IFN-β signalling in the induction
of IDO during RSV infection. Additionally, we used various PRR pathway inhibitors to
determine their roles in the expression of IFN-β in response to RSV, demonstrating a
potential pathway from RSV recognition by MSCs to downstream immune regulation.
6.2 IFN-β signaling drives IDO production in RSV-infected MSCs
Next the hypothesis that IFN-β signaling was driving the expression of IDO in
MSCs infected by RSV was investigated. Using a neutralizing antibody we blocked IFNβ signaling through its surface receptor. Briefly, 10 μg per ml of the anti-IFN-β antibody
was added to the culture supernatant of MSCs infected with RSV immediately following
infection. After 72 hours the supernatants were removed and RNA was collected by the
TRIzol method, as previously described, to examine the effect of blocking IFN-β on IDO
expression.
Blocking IFN-β signaling with a neutralizing antibody reduced IDO expression in
RSV-infected MSCs compared with untreated cells (Figure 14a). Cell lysates from cells
with showed significantly lower IDO protein, measured by ELISA, as well as IDO
enzymatic activity, measured by tryptophan catabolism assay (Figure 14b and c).
Untreated RSV-infected MSCs had a mean activity of 48.76 units of IDO per μg lysate
compared to infected MSCs blocked with anti-IFN-β, which had a mean activity of 18.85
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units per μg lysate. This reduction in RSV-induced IDO gene expression (9.6-fold in
anti-IFN-β treated versus 24.9-fold in untreated cells) was not due to a reduction in IFNβ transcript epression (Figure 14d). This established the involvement of the IFN-β
signaling pathway in IDO-induction during RSV infection of MSCs.
6.3 The role of the RIG-I and endosomal TLR pathways in IFN-β induction during
RSV infection of MSCs
To examine the upstream PRR signaling leading to IFN-β expression and
signaling during RSV infection, and subsequent IDO expression and activity, a series of
inhibitors were used. In the first series of experiments a RIG-I pathway inhibitor BX795,
which blocks phosphyrlation and thereby catalytic activity of TBK1/IKKε [158], was used
as well as chloroquine, a broad inhibitor of endosomal pathways including endosomal
TLR signaling [159, 160] through TLR3, 7, 8, and 9. As described previously, MSCs
were infected with RSV and then cultured in the presence of either normal MSC growth
media or growth media containing one of the inhibitors. After 72 hours the RNA, cell
lysates, and supernatants were collected and used to measure IFN-β and IDO
transcripts, IDO protein and activity, and PFU production by RSV.
Expression of IFN-β was significantly reduced in MSCs treated with chloroquine
(121.7-fold versus 285.3 in untreated cells; p = 0.002), while the BX795 group did not
show a statistical difference in IFN-β transcripts (201.6-fold; p = 0.135) (Figure 15a).
IDO expression was only 3.7-fold for chloroquine treatment versus 31.2-fold for BX795
treatment and 24.9-fold in untreated infected MSCs (Figure 15b). ELISA of cell lysates
showed a significant drop in IDO protein concentration in chloroquine treatment (240.7
pg per μg lysate) versus untreated cells (355.0 pg per μg lysate; p = 0.0009) while
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BX795 was not statistically different (395.3 pg per μg lysate) (Figure 15c). Activity of
IDO, measured by tryptophan catabolism, was significantly reduced in chloroquinetreated cells as well (22.95 units of IDO per μg lysate) compared with untreated cells
(48.76 units of IDO per μg lysate; p = 0004) (Figure 15d). These changes in expression
were not due to an effect of the inhibitors on RSV infectivity or replication, measured by
PFU in the culture supernatant (Figure 15e).
Similar to the treatment with the anti-IFN-β antibody reported above treating the
cells with chloroquine reduced IDO protein detected by ELISA as well as enzymatic
activity in lysates from infected cells, while cells treated with the RIG-I pathway inhibitor
BX795 were unaffected. These results indicate that endosomal TLR pathways may be
responsible for recognizing and responding to RSV infection in MSCs, triggering IFN-β
expression and downstream IDO expression and activity.
6.4 Blocking TLR7/8/9 and TLR3 signaling with specific inhibitors
To determine the endosomal pathway or pathways responsible for the IFN-β
response to RSV in MSCs we used two specific inhibitors; ODN 2088, a short singlestranded inhibitory oligodeoxynucleotide (ODN) that antagonizes CpG ODN-mediated
activation of TLR9 as well as inhibiting TLR7 and TLR8 activity [161-163] and
TLR3/dsRNA Complex Inhibitor, a direct competitive and high affinity inhibitor of dsRNA
binding to TLR3 [96].
For ODN 2088, MSCs were infected with RSV and then grown in MSC growth
media with the inhibitors or no inhibitor (vehicle for ODN 2088). After 72 hours of
infection the RNA was collected and used to measure IFN-β, IDO, TLR3 and RSVN
transcript production by RSV infected cells. Results showed that ODN 2088 treatment
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did not change how MSCs responded to RSV infection in terms of their IFN-β
expression (73.4-fold vehicle versus 66.9-fold ODN 2088, p = 0.182); IDO expression
(63.3-fold versus 66.8-fold, p = 0.5143); or TLR3 expression (26.7-fold versus 27.2-fold,
p = 0.72).
For the TLR3/dsRNA complex inhibitor, MSCs were infected as described
previously and grown in the presence of TLR3-inhibitor or DMSO (vehicle control for the
TLR3-inhibitor) for 24 and 48 hours before RNA was collect by TRIzol. Results showed
that TLR3-inhibitor treatment caused a drop in IFN-β transcripts; from 33.9-fold to 22.4fold (p = 0.049) at 24 hours and 115.4-fold to 44.8-fold (p = 0.002) at 48 hours post
infection (Figure 17a and d). Similarly, IDO transcripts were lower in the TLR3-inhibitor
treatment group, 2.8-fold (DMSO: 10.2-fold, p < 0.0001) at 24 hours and 6.8 (DMSO:
14.7-fold, p < 0.0001) at 48 hours (Figure 17c and f). As an IFN-β-inducible gene, TLR3
expression was also affected later in the infection. At 24 hours the TLR3-inhibitor group
was similar to the vehicle-treated cells, 20.5-fold and 22.1-fold respectively (p = 0.97).
However, at 48 hours the vehicle group increased expression of TLR3 to 49.0-fold while
the TLR3-inhibitor treatment remained at 21.0-fold (p = 0.002) (Figure 17b and e).
These results, and those presented previously, show a plausible pathway
connecting the detection of RSV products by PRRs, the production of virus-stimulated
genes, and the regulation of immune cell proliferation.
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Figure 14. IFN-β antagonism reduces RSV-induced IDO expression and activity
Incubation of infected cells with a neutralizing antibody against IFN-β was able to
reduce IDO expression, protein, and activity (A, B, and C) without any effect on IFN-β
transcript levels (D) or plaque-forming units in the supernatant (E). Significance
determined by one-way ANOVA with Fisher’s LSD test. Error bars represent SEM, n =
3. *** p < 0.001 **** p < 0.0001
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Figure 15. Endosomal TLR- and not RIG-I-pathway-inhibitors block IFN-β
induction and IDO expression in RSV-infected MSCs
Infected MSCs treated with the endosomal TLR-pathway inhibitor chloroquine
expressed lower levels of IDO and IFN-β versus non-treated cells while the RIG-I
inhibitor BX795 had no effect (A, B). IDO protein and enzymatic activity measured from
cell lysates were reduced in cells treated with chloroquine but not BX795 (C, D) despite
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non-significant differences in RSV PFU production (E). Significance between groups
determined by one-way ANOVA with Fisher’s LSD test. Error bars represent SEM, n =
3. ** p < 0.01, *** p < 0.001, **** p < 0.0001
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Figure 16. The TLR7/8/9 antagonist inhibitory ODN 2088 has no effect on RSVstimulation of IFN-β, IDO, or TLR3
MSCs infected for 72 hours showed no significant changes response to ODN
2088 treatment in respect to IFN-β (A), IDO (B), or TLR3 (C) expression. RSV infection,
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measured by RSVN transcripts, was unaffected by the TLR7/8/9 inhibitor. Expression
normalized to mock-infected vehicle control; Statistical significance determined by 2way ANOVA; n = 3.

65

A.

B.

C.

IFNB

TLR3

40
30
20
10
0

D.

20

10

0

DMSO TLR-3 inhibitor

E.

0

DMSO TLR-3 inhibitor

DMSO TLR-3 inhibitor

IDO

**

60

20
Normalized Fold Expression

50

5

TLR3

***

100

10

F.

Normalized Fold Expression

Normalized Fold Expression

150

****

0

DMSO TLR-3 inhibitor

IFNB

48 hours p.i.

15
Normalized Fold Expression

*

IDO

ns

30
Normalized Fold Expression

24 hours p.i.

Normalized Fold Expression

50

40

20

0

DMSO TLR-3 inhibitor

Mock

****
15

10

5

0

DMSO TLR-3 inhibitor

RSV

Figure 17. Antagonizing the TLR3-signaling pathway reduces IFN-β, IDO and
TLR3 in RSV infected MSCs
Infected MSCs treated with the TLR3/dsRNA complex inhibitor expressed lower
levels of IFN-β (A,D) and IDO (C,F) transcripts at 24 and 48 hours post infection
compared with vehicle-treated cells. At 24 hours the expression of TLR3 was not
different (B) however while vehicle-treated cells increased TLR3 expression by 48 hours
the inhibitor-treated cells did not increase expression (E). Expression normalized to
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mock-infected DMSO control; Statistical analysis by 2-way ANOVA; n = 3. * p < 0.05, **
p < 0.01, *** p < 0.001, **** p < 0.0001
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Chapter 7: Evaluation of the in vivo mouse model of RSV infection for
investigating the role of MSCs and IDO

7.1 Introduction
Animal models are particularly important in the development of RSV vaccines
and therapeutic treatments; especially in light of the failed formalin-inactivated vaccine
of the 1960s [164], a disastrous clinical trial that still overshadows the field of RSV
vaccine development to this day. It was not until decades later when a cotton rat model
was able to reproduce the vaccine-enhanced disease that the mechanism behind the
failed trial could be explored [165, 166].
RSV studies have been done in chimpanzees [167], rhesus monkey [167],
African green monkey [168], and other primates [169], however use of these animals is
typically limited due to funding and ethical concerns, and costs may result in difficulties
obtaining sample sizes large enough to gain statistical significance [170]. Additionally,
justification for the use of these animals is problematic due to the cheaper and less
ethically frowned on animal models available. The ovine model, for example, has been.
Cotton rat [171] and inbred mouse [172] are the two most published animal models of
RSV infection, with mouse being the most used in the field. The cotton rat is more
susceptible to RSV infection, taking a hundred-fold lower dose to cause disease than
mouse, and responds with a antibody titers that are reported to be 10-fold or more
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higher [172, 173]. However, drawbacks to the model include a lack of reagents such as
monoclonal antibodies compared to mice. Additionally, the mouse model can make use
of a vast library of inbred knockout and transgenic strains that are unavailable in any
other animal model. In addition to the genetics and reagents other advantages include
the relative ease compared to other animals of housing and maintaining the number of
mice needed for a statistically sound study; the size per subject allowing for lower cost
of drug and vaccine candidates; and mice have been shown to be permissive to the
virus [172], although not so permissive as cotton rats.
The ultimate goal of the following work was to utilize an in vivo model to
investigate the consequences of MSC infection with RSV. The mouse model was
chosen and evaluated based on the lab’s experience utilizing the mouse in RSV
research in addition to the considerations listed above. The results of these experiments
showed that we could reproduce the findings reported by Rezaee et al. in 2011 [76].
However, we also revealed differences in the response of human and murine MSCs to
infection with RSV in regards to IDO versus iNOS expression.
7.2 RSV infects and replicates in mouse MSCs
Mouse MSCs were grown out from bone marrow cultures and tested for MSC
markers CD105, CD29, and Sca-1 and negative for the CD45 surface markers (Mouse
Mesenchymal Stem Cell Multi-Color Flow Kit, R&D Systems, Minneapolis, MN) as
described previously [174]. Early passage MSCs were infected at 1 MOI for 72 hours
before imaging with a fluorescent microscope. mKate2-expression was used as an
indicator of RSV infection. To confirm this result infected MSCs were grown on
coverslips and stained for with an anti-RSV antibody conjugated to FITC, as previously
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described. Results showed that mouse MSCs, like human MSCs, are capable of being
infected by RSV (Figure 18).
7.3 RSV transcripts detected in bone marrow cells of infected animals
After ensuring mouse MSCs could be infected in vitro with human RSV we infected
wild type Balb/c mice with 2 million PFUs of RSV intranasally. After 5 days of infection the
lungs were isolated for immunohistochemistry using the previously described method.
Sections of mouse lung were prepared by fixing and embedding the lung in OCT media prior
to sectioning in a cryomicrotome and staining the sections with a polyclonal goat anti-RSV
antibody. RSV in the lung was detected by a donkey anti-goat secondary antibody
conjugated to Alex Fluor 555 (Figure 19a). In addition to the lung, bone marrow was flushed
from the long bones of the hind legs and used for RNA and PFU assay. After isolation by
TRIzol method RNA from the bone marrow cells was examined for RSV gene expression by
RTqPCR. Results showed a low level of RSVN detected in the infected animals (Figure
19b). However, no PFUs were detectable in any of the bone marrow aspirates. These
results were reproducible through several experiments. These results indicated that, like
fresh human bone marrow isolates, RSVN transcripts can be detected in mouse marrow
following infection. However, no infective virions were detected in the bone in any of our
experiments. This indicates that either there is too low a number of RSV virions a PFU
assay or the infection of the mouse bone marrow is nonproductive.
7.4 RSV infection in IDO-deficient mice
To examine the effects of IDO on the infection in an in vivo model we utilized an
IDO-knockout strain, B6.129-Ido1tm1Alm/J. Mice were infected with 3 million PFUs of RSV
intranasally for 5 days before euthanasia and collection of lungs for
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immunohistochemistry, RNA, and PFU assay. Lungs for immunohistochemistry were
fixed, cryopreserved, embedded in OCT, and sectioned as described previously. These
sections were stained for RSV infection using a goat anti-RSV polyclonal primary
antibody and a secondary anti-goat antibody labeled with Alexa Fluor 555. After
mounting with anti-fade medium containing DAPI the sections were imaged using a
fluorescent microscope. There was no difference in the amount of RSV staining,
measured by red fluorescence, in the IDO-deficient mice versus wild type (Figure 20a).
Further, RSVN expression (Figure 20b) and PFUs collected from the lung (Figure 20c)
were not significantly different between the two strains of mice. There was also no
statistically significant difference in IFN-β expression between the IDO-deficient strain
and the wild type mice (Figure 20d). Interstingly, IDO was induced following RSV
infection in the wild type mice to 146.8-fold the mock levels (p = 0.004, Figure 20e).
7.5 RSV infection of mouse MSCs induces iNOS and not IDO
After the previous result we wanted to determine whether the mouse presented
an appropriate model for examination of IDO expression by MSCs in response to RSV
infection. Therefore, wild type mouse bone marrow-derived MSCs, collected from the
bones of the hind legs of mice, were grown for 3 passages before infection with RSV.
72 hours post infection RNA was isolated and examined for IDO expression as well as
IFN-β and inducible nitric oxide synthase (iNOS). Results showed that RSV induced
128.2-fold increase of IFN-β transcripts (p = 0.0029), however IDO expression was
unchanged (p = 0.23, Figure 21a and b). Interestingly, iNOS was highly transcribed
following RSV infection at 594.1-fold the mock level (p = 0.0015, Figure 21c).
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These results stand in contrast to what has been reported above in human MSCs
(Figure 8) and suggest that RSV infection in mice, both in vitro and in vivo, may be an
unsuitable model for examining the role of MSCs in RSV infections, at least as it
pertains to IDO activity.
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Figure 18. RSV infection of mouse MSCs
Mouse bone marrow-derived MSCs isolated from transgenic mice expressing
GFP (C57BL/6-Tg(CAG-EGFP)131Osb/Ley SOPJ, Jackson Labs) were infected with
RSV expression the fluorescent molecule mKate2 (red). After 72 hours fluorescent
micrographs were captured to confirm the infection (A). RSV-infected wild type C57BL/6
MSCs stained with the anti-RSV-FITC antibody confirmed the results (B).
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Figure 19. RSV transcripts in bone marrow of RSV infected mice
Lungs of mice infected with RSV were fixed in 4%PFA overnight, then
cryopreserved in sucrose solution before embedding in OCT media. 5μm sections were
stained with a primary goat polyclonal antibody against RSV and a secondary donkey
anti-goat antibody conjugated to Alexa Fluor 555 (red). Stained sections were mounted
with anti-fade and DAPI (blue) for imaging with a fluorescent microscope (A). H&E
staining for lung structure was also performed (mock top panel, RSV bottom). RSVN
transcript was detected in bone marrow aspirates (n = 4 mice) (B). ** p < 0.01 vs. mock
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mice (D), however only wildtype showed increased IDO in response to RSV infection
(E). ** p < 0.01, *** p < 0.001 vs mock
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Figure 21. Mouse MSCs express iNOS but not IDO in response to RSV infection
RSV-infected mouse MSCs expressed high levels of IFN-β 72 hours following
infection (A). IDO transcripts were not significantly different between the mock and
infected groups at 72 hours (B). Infected MSCs did have high levels of iNOS mRNA (C)
and RSVN expression confirmed infection (D). Results typical of repeated experiments
in bone-derived mouse MSCs. Significance determined using Students T test
comparing mock and infection, n = 3. ** p < 0.01
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Chapter 8: Conclusions

To date most RSV research has focused on the viral modulation of innate
immune signaling within immortalized epithelial cell lines such as HEp-2 and A549
although recent reports of RSV infecting and replicating in cells of the immune system
including blood and lung neutrophils [73-75, 175], macrophages [98-100], and dendritic
cells [70, 176, 177] suggest that RSV is capable of infecting cells of non-epithelial origin.
Though extrapulmonary RSV infection of MSCs in humans was reported [76, 178], little
is known about its role in virus-mediated immune regulation and the lack of protective
immunity on subsequent secondary RSV infection. Our study addressed the role of
MSCs as a target cell for RSV and the consequences of this extra-epithelial infection
and is the first to report an increase in the expression of the immune regulatory factors
IFN-β and IDO.
Our findings demonstrate that RSV infects MSCs in vitro and infective virus
progeny are produced by the MSCs. This observation is similar to the other reports [76,
178]. Infection of MSCs would require the virus to infect beyond the apical epithelial
layer of the airway, a phenomenon that has been demonstrated in ovine and baboon
animal models [169, 179]. In vitro air-liquid culturing of NHBE cells has allowed
researchers to examine this further, demonstrating that RSV can gain access to and
infect the basal progenitor cells beneath by epithelial denuding or physical damage to
the apical cells [38, 180]. Similar mechanisms may permit RSV to gain access to airway
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stromal cells such as MSCs. While scarce, tissues of infants and adults who have
succumbed to severe RSV could go long way in determining whether the virus truly
infects MSCs during the course of the disease. In one of the few studies of autopsy
tissues RSV antigens were found throughout the lung but were most concentrated in
areas where the airway epithelium was exfoliated [181], which in theory would provide
access for the virus to sub-epithelial cell types like stromal cells.
We sought to identify factors that could be important in mediating the effects of
RSV in MSCs by examining differential expression of chemokines and cytokines
involved in the inflammatory response. Unlike with RSV-infected NHBE cells, RSVinfected MSCs showed no change in the mRNA of the proinflammatory cytokines IL-6 or
SDF-1 (CXCL12). However, there was a significant increase in the expression of the
chemokine IL-8 (CXCL8), which is known for neutrophil recruitment and may be
involved in mediating the inflammation and neutrophilia associated with severe RSV
infections. Also, since neutrophils are susceptible to RSV [73] and are known to return
to the bone marrow upon senescence [182, 183] they may contribute to the
extrapulmonary RSV infection of bone MSCs observed by others [76, 178].
A major finding from our study relates to modulation of interferon expression and
signaling by RSV-infected MSCs. Our results showed that when infected with RSV both
NHBE and MSCs displayed significant upregulation of IFN-β, but not in IFN-γ or IFN-α.
The functional relevance of this finding is unclear as RSV continues to replicate in
MSCs and blocking IFN-β signaling with a neutralizing antibody did not increase or
decrease virus replication. It is possible that RSV-induced IFN-β-signaling simply may
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not be protective and/or represent a “high jacked” immune regulatory pathway in the
case of RSV infection of MSCs.
Regulation of immunity by MSCs has been linked to active TLR signaling [184189] and products of RSV replication are known TLR ligands [44, 190, 191]. The results
of our study showed chloroquine treatment of infected MSCs was sufficient to block
IFN-β expression, which suggests that endosomal TLR recognition of viral products
plays a key role in the MSC response to RSV infection. These results are similar to
those reported for adenovirus and baculovirus, which induce an increased expression
and TLR signaling in MSCs as well as increased IFN-β production [192]. Since RSV
also stimulates immunity via the RNA helicase RIG-I through activation of the
mitochondrial antiviral signaling complex (MAVS), TBK-1/IKKε, and IRF3 [193, 194], the
role of this pathway in RSV infected MSCs was examined. Our results that the
TBK1/IKKε inhibitor BX795 did not affect RSV-stimulated IFN-β expression suggest that
the RIG-I pathway is not involved in this aspect of the MSC response to the virus.
Another major finding from our studies is that although MSCs produce a number
of immune regulatory factors including iNOS, IL-1Ra, and PGE2 [86, 88, 195, 196], none
of these were altered in their expression during RSV infection. However, RSV-infected
MSCs did show a significant increase in IDO transcripts and protein, as well as activity
of the enzyme. Further, RSV-infected MSCs exerted a greater inhibition of mitogenstimulated proliferation of human PBMCs through IDO activity. Antagonizing IDO activity
with a competitive inhibitor such as 1-MT or vitamin K3 [95] reduced kynurenine levels in
conditioned media of RSV infected MSCs and reversed the suppressive effect of MSC
CM on lymphocyte proliferation, although these inhibitors did not affect RSV infective
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rate or proliferation in MSCs. In agreement with this, bone marrow cells isolated from
IDO deficient mice were infected by RSV equally as the wild type mice. These results
suggest that the use of an IDO inhibitor during respiratory viral infection could result in a
boosted immune response. This idea is consistent with a report which demonstrated
that pretreatment of influenza-infected mice with 1-MT, increased inflammatory markers,
such as IL-6, TNF-α and IFN-β [139], and Th1 cell numbers and boosted the secondary
immune response [140].
In the report presented we found that blocking IFN-β signaling with a neutralizing
antibody resulted in reduced IDO expression and enzymatic activity in infected MSCs.
This conclusion agrees with reports in other immune cells showing an IFN-γindependent pathway in the production of IDO involving IFN-β [154, 155]. In contrast to
IFN-γ-stimulated IDO, which plays the role of the canonical enzyme in the catabolism of
tryptophan, IFN-β-induced IDO acts as a signaling molecule; recruiting Src homology
region 2 domain-containing phosphatase (SHP)-1 and SHP-2, leading to noncanonical
NF-κB pathway activation with RelB/p52, and promoting IFN-β and TGF-β production in
a positive feedback loop leading to increased IDO and immune regulation [157, 197199]. In this study treatment of mouse DCs with TGF-β induced an increase in IDO and
a tolerogenic profile that was not due to tryptophan degradation or kyneurinine
production. The authors demonstrated that TGF-β-associated tolerogenic effects in
pDCs [200] were prevented by IDO gene silencing, but not by the use of 1-MT, an
inhibitor of IDO enzyme activity [201]. Further, they discovered that IDO contains two
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, when phosphorylated,
lead to the binding of either SOCS3 and eventual ubiquitin-mediated proteasomal
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degradation [202] or the tyrosine phosphatases SHP-1 and SHP-2 which leads to noncanonical NF-κB activation and a positive feedback loop involving expression of IFN-β
and IDO [201] leading to the formation of long-term tolerogenic DCs [200]. While IDO
enzymatic activity was shown in our work to play an important role in the regulation of
PBMC activation this alternative pathway could also be involved, however this was not
investigated during this study. In lieu of the knockout animal model, about which the
work presented here has raised questions, a future study could utilize the
CRISPR/Cas9 knockout technique in human MSCs to investigate whether removing the
gene recapitulates the results found here. Additionally, investigation of the interaction of
the SHP tyrosine phosphatases with IDO could unveil whether this non-enzymatic
mechanism of IDO activity is involved or not during RSV infection of human MSCs.
The results of the PRR-pathway inhibitors demonstrated that chloroquine, the
endosomal TLR inhibitor, but not BX795, the RIG-I pathway inhibitor, could reduce the
RSV-stimulated IFN-β and IDO expression in MSCs. Further, upon interrogation of the
endosomal TLRs with either inhibitory ODN 2088, a TLR7/8/9 antagonist, or
TLR3/dsRNA complex inhibitor we found that TLR3 but not TLR7/8/9 play a role in this
response to RSV in MSCs. These results together with the IFN-β neutralization study
demonstrate a role for TLR3-stimulated IFN-β in the induction of IDO in MSCs. It is
possible this IFN-β-dependent pathway is also active in other cell types during RSV
infection, such as macrophages and apical cells of the airway epithelium, which also
play a role in regulation of the immune system and could be a target for blocking
immune regulation by IDO during viral infection.
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Our findings with MSCs differ from a recent report on IDO expression in which
monocyte-derived dendritic cells (moDCs) were infected with recombinant green RSV
[72]. This study indicated that the induction of IDO and IFN-γ were due to RIG-I pathway
activity and not endosomal TLRs. Interestingly, in contrast to moDCs the RSV-infected
MSCs used in the work presented here showed an increase in IFN-β, not in IFN-γ, and
similar findings were shown with NHBE cells. This result is similar to those previously
reported in other epithelial cell lines where RSV has been found to antagonize IFN-γ
expression by inhibition of RIG-I pathway molecules via RSV nonstructural proteins [38,
40]. These discrepancies suggest that the cell types used in each study may differ in
their activation of molecular pattern recognition receptors and subsequent signaling,
perhaps due to their differential susceptibility to RSV. The convergence of both cellular
response pathways in the induction of IDO is an interesting finding, regardless. Future
work could focus on the different viral response pathways triggered by classical antigen
presenting cells such as monocytes and DCs compared to non-classical immune
regulators like epithelial and stromal cells.
When translating these in vitro findings to the animal model we encountered
some issues. The results gathered from IDO-knockout mouse experiments found no
difference in the number of RSV PFU in the lungs of IDO-knockout versus wild type
C57Bl/6 mice. One possible reason could be the reported disparity between mice and
men in the immune-regulatory role of IDO. For example, in humans IDO has been
shown to be induced in listeriosis and tuberculosis, however murine models of each of
these diseases suggest that iNOS and not IDO is induced in mice [203]. In line with this,
other reports have suggested that activated murine MSCs utilize iNOS in their immune
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regulatory function, while human MSCs exert their effects via IDO under the same
stimuli [204, 205]. Our findings using wild type mouse MSCs infected with RSV agree
with these studies. We found no IDO expression following RSV infection of mouse
MSCs and instead showed the induction of iNOS, a gene that was not expressed in
human MSCs following RSV infection. Recently a group reported the use of a
humanized mouse MSC model in which MSCs produced IDO under the control of the
iNOS promoter [206]. Given these results showing the importance of MSCs in RSV
pathogenesis and anti-RSV immunity a similar strategy may be useful to further
elucidate the importance of IDO produced by RSV-infected MSCs. It is possible that this
difference in IDO versus iNOS expression by stromal cells may play a role in the
dissimilarities seen in RSV replication and response between mice and humans and
also may account for the inability of the murine model of RSV infection to fully
recapitulate the human disease [207-209]. Additionally, different strains of mouse have
been found to be more or less permissive [172], and it is possible that strain variation in
MSC expression of IDO, which has also been reported [210], may play a role in this
variation in RSV permissiveness. The fact that MSCs from Balb/c, an
immunocompromised mouse strain often utilized in the study of RSV, express more IDO
than C57BL/6 could indicate that they are a better strain for the in vivo investigation of
the role of MSCs in RSV infection. A future study could investigate whether IDO
expression correlates with RSV permissiveness in mice and other animal models such
as the cotton rat. Additionally, one could conceive of a murine model involving
transgenic over-expression of IDO in the lung in order to increase mouse susceptibility
to RSV and create a more similar disease at a lower infective dose.
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In summary, these results provide the first report that RSV infection of human
bronchial epithelial cells and MSCs results in expression of the immune regulatory
molecule IDO, which may be involved in disrupting the development of protective
immunity against subsequent infections with the virus. Inhibition of virus-induced IDO
production or activity may be a viable target for developing more effective therapies to
respiratory viral pathogens. These results have implications beyond RSV-induced lung
diseases, since the use of MSCs is being investigated in several areas of medicine
including reducing rejection rates in solid organ transplantation, as cell-based therapy
for autoimmune disease, as well as use in regenerative medicine [86-88, 196, 211]. A
database search at ClinicalTrials.gov for the terms “Mesenchymal Stem Cells” returned
304 open studies demonstrating the high level of interest in the use of these cells in a
clinical setting. This underscores the importance of understanding the mechanisms of
viral enhancement of their immune regulatory function, which may lead to procedures
that optimize this feature for regulatory or regenerative applications.

85

References

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

Hall, C.B., et al., The Burden of Respiratory Syncytial Virus Infection in Young
Children. New England Journal of Medicine, 2009. 360(6): p. 588-598.
Yamazaki, H., et al., Effect of maternal antibody on IgA antibody response in
nasopharyngeal secretion in infants and children during primary respiratory
syncytial virus infection. J Gen Virol, 1994. 75 ( Pt 8): p. 2115-9.
From the American Academy of Pediatrics: Policy statements--Modified
recommendations for use of palivizumab for prevention of respiratory syncytial
virus infections. Pediatrics, 2009. 124(6): p. 1694-701.
Lofland, J.H., et al., Palivizumab for respiratory syncytial virus prophylaxis in
high-risk infants: a cost-effectiveness analysis. Clin Ther, 2000. 22(11): p. 135769.
Falsey, A.R., et al., Respiratory syncytial virus infection in elderly and high-risk
adults. N Engl J Med, 2005. 352(17): p. 1749-59.
Falsey, A.R. and E.E. Walsh, Respiratory syncytial virus infection in elderly
adults. Drugs Aging, 2005. 22(7): p. 577-87.
Stockman, L.J., et al., Respiratory syncytial virus-associated hospitalizations
among infants and young children in the United States, 1997-2006. Pediatr Infect
Dis J, 2012. 31(1): p. 5-9.
Cabalka, A.K., Physiologic risk factors for respiratory viral infections and
immunoprophylaxis for respiratory syncytial virus in young children with
congenital heart disease. Pediatr Infect Dis J, 2004. 23(1 Suppl): p. S41-5.
Meissner, H.C., et al., Risk of severe respiratory syncytial virus disease,
identification of high risk infants and recommendations for prophylaxis with
palivizumab. Pediatr Infect Dis J, 2004. 23(3): p. 284-5.
Manzoni, P., et al., High risk for RSV bronchiolitis in late preterms and selected
infants affected by rare disorders: a dilemma of specific prevention. Early Hum
Dev, 2012. 88 Suppl 2: p. S34-41.
Lacaze-Masmonteil, T., et al., Lower respiratory tract illness and RSV
prophylaxis in very premature infants. Archives of Disease in Childhood, 2004.
89(6): p. 562-567.
Broughton, S., et al., Diminished lung function, RSV infection, and respiratory
morbidity in prematurely born infants. Archives of Disease in Childhood, 2006.
91(1): p. 26-30.
Sigurs, N., et al., Asthma and allergy patterns over 18 years after severe RSV
bronchiolitis in the first year of life. Thorax, 2010. 65(12): p. 1045-52.

86

14.
15.
16.
17.

18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.

Resch, B., et al., Respiratory syncytial virus-associated hospitalizations over
three consecutive seasons in children with congenital heart disease. Eur J Clin
Microbiol Infect Dis, 2016.
MacDonald, N.E., et al., Respiratory syncytial viral infection in infants with
congenital heart disease. N Engl J Med, 1982. 307(7): p. 397-400.
Lanari, M., et al., High risk of nosocomial-acquired RSV infection in children with
congenital heart disease. J Pediatr, 2004. 145(1): p. 140; author reply 140-1.
Madhi, S.A., et al., Differing manifestations of respiratory syncytial virusassociated severe lower respiratory tract infections in human immunodeficiency
virus type 1-infected and uninfected children. Pediatr Infect Dis J, 2001. 20(2): p.
164-70.
Leader, S. and K. Kohlhase, Recent trends in severe respiratory syncytial virus
(RSV) among US infants, 1997 to 2000. J Pediatr, 2003. 143(5 Suppl): p. S12732.
Thompson, W.W., et al., Mortality associated with influenza and respiratory
syncytial virus in the United States. JAMA, 2003. 289(2): p. 179-86.
Mandell, L.A., et al., Update of practice guidelines for the management of
community-acquired pneumonia in immunocompetent adults. Clin Infect Dis,
2003. 37(11): p. 1405-33.
Wong, T.M., et al., Respiratory Syncytial Virus (RSV) Infection in Elderly Mice
Results in Altered Antiviral Gene Expression and Enhanced Pathology. PLoS
One, 2014. 9(2): p. e88764.
Kapikian, A.Z., et al., An epidemiologic study of altered clinical reactivity to
respiratory syncytial (RS) virus infection in children previously vaccinated with an
inactivated RS virus vaccine. Am J Epidemiol, 1969. 89(4): p. 405-21.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody,
reduces hospitalization from respiratory syncytial virus infection in high-risk
infants. The IMpact-RSV Study Group. Pediatrics, 1998. 102(3 Pt 1): p. 531-7.
Meissner, H.C. and S.S. Long, Revised indications for the use of palivizumab
and respiratory syncytial virus immune globulin intravenous for the prevention of
respiratory syncytial virus infections. Pediatrics, 2003. 112(6 Pt 1): p. 1447-52.
Meissner, H.C. and D.W. Kimberlin, RSV immunoprophylaxis: does the benefit
justify the cost? Pediatrics, 2013. 132(5): p. 915-8.
Glenn, G.M., et al., Safety and immunogenicity of a Sf9 insect cell-derived
respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine, 2013.
31(3): p. 524-32.
DeVincenzo, J., et al., Evaluation of the safety, tolerability and pharmacokinetics
of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory
syncytial virus (RSV). Antiviral Res, 2008. 77(3): p. 225-31.
DeVincenzo, J., et al., A randomized, double-blind, placebo-controlled study of
an RNAi-based therapy directed against respiratory syncytial virus. Proceedings
of the National Academy of Sciences, 2010. 107(19): p. 8800-8805.
Zamora, M.R., et al., RNA Interference Therapy in Lung Transplant Patients
Infected with Respiratory Syncytial Virus. American Journal of Respiratory and
Critical Care Medicine, 2011. 183(4): p. 531-538.

87

30.

31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

Mejías, A., et al., Comparative Effects of Two Neutralizing Anti-Respiratory
Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time
versus Potency. Antimicrobial Agents and Chemotherapy, 2005. 49(11): p. 47004707.
Corti, D., et al., Cross-neutralization of four paramyxoviruses by a human
monoclonal antibody. Nature, 2013. 501(7467): p. 439-43.
Carbonell-Estrany, X., et al., Motavizumab for prophylaxis of respiratory syncytial
virus in high-risk children: a noninferiority trial. Pediatrics, 2010. 125(1): p. e3551.
Jafri, H.S., et al., Distribution of respiratory syncytial virus subtypes A and B
among infants presenting to the emergency department with lower respiratory
tract infection or apnea. Pediatr Infect Dis J, 2013. 32(4): p. 335-40.
Fields, B.N., et al., Fields' virology / editors-in-chief, David M. Knipe, Peter M.
Howley ; associate editors, Diane E. Griffin ... [et al.]. 4th ed. ed. 2001,
Philadelphia: Lippincott Williams & Wilkins.
Fearns, R. and P.L. Collins, Role of the M2-1 transcription antitermination protein
of respiratory syncytial virus in sequential transcription. J Virol, 1999. 73(7): p.
5852-64.
Evans, J.E., P.A. Cane, and C.R. Pringle, Expression and characterisation of the
NS1 and NS2 proteins of respiratory syncytial virus. Virus Res, 1996. 43(2): p.
155-61.
Spann, K.M., K.C. Tran, and P.L. Collins, Effects of nonstructural proteins NS1
and NS2 of human respiratory syncytial virus on interferon regulatory factor 3,
NF-kappaB, and proinflammatory cytokines. J Virol, 2005. 79(9): p. 5353-62.
Ling, Z., K.C. Tran, and M.N. Teng, Human respiratory syncytial virus
nonstructural protein NS2 antagonizes the activation of beta interferon
transcription by interacting with RIG-I. J Virol, 2009. 83(8): p. 3734-42.
Munir, S., et al., Respiratory Syncytial Virus Interferon Antagonist NS1 Protein
Suppresses and Skews the Human T Lymphocyte Response. PLoS Pathog,
2011. 7(4): p. e1001336.
Boyapalle, S., et al., Respiratory syncytial virus NS1 protein colocalizes with
mitochondrial antiviral signaling protein MAVS following infection. PLoS One,
2012. 7(2): p. e29386.
Morgan, L.A., et al., Strain variation of respiratory syncytial virus. J Gen Virol,
1987. 68 ( Pt 11): p. 2781-8.
Krusat, T. and H.J. Streckert, Heparin-dependent attachment of respiratory
syncytial virus (RSV) to host cells. Arch Virol, 1997. 142(6): p. 1247-54.
Hallak, L.K., et al., Iduronic acid-containing glycosaminoglycans on target cells
are required for efficient respiratory syncytial virus infection. Virology, 2000.
271(2): p. 264-75.
Kurt-Jones, E.A., et al., Pattern recognition receptors TLR4 and CD14 mediate
response to respiratory syncytial virus. Nat Immunol, 2000. 1(5): p. 398-401.
Behera, A.K., et al., Blocking intercellular adhesion molecule-1 on human
epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys
Res Commun, 2001. 280(1): p. 188-95.

88

46.
47.

48.
49.

50.

51.
52.
53.

54.
55.
56.
57.
58.
59.

Zhang, W., et al., Vaccination to induce antibodies blocking the CX3C-CX3CR1
interaction of respiratory syncytial virus G protein reduces pulmonary
inflammation and virus replication in mice. J Virol, 2010. 84(2): p. 1148-57.
Rallabhandi, P., et al., Respiratory Syncytial Virus Fusion Protein-Induced TollLike Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists
Rhodobacter sphaeroides Lipopolysaccharide and Eritoran (E5564) and
Requires Direct Interaction with MD-2. mBio, 2012. 3(4): p. e00218-12.
Haynes, L.M., et al., Involvement of toll-like receptor 4 in innate immunity to
respiratory syncytial virus. J Virol, 2001. 75(22): p. 10730-7.
Boukhvalova, M.S., et al., Activation of interferon response through toll-like
receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression
during respiratory syncytial virus and influenza infections in the cotton rat
Sigmodon hispidus model. J Interferon Cytokine Res, 2010. 30(4): p. 229-42.
Lukacs, N.W., et al., Respiratory Virus-induced TLR7 activation controls IL-17
associated Increase in mucus via IL-23 regulation: Respiratory virus induced
immune environment relies on TLR7-mediated pathways to preserve a nonpathogenic response and regulates IL-17 production. Journal of immunology
(Baltimore, Md. : 1950), 2010. 185(4): p. 2231-2239.
Respiratory Syncytial Virus Surveillance - RSV National Trends. 2016 April 15,
2016 [cited 2016 May 27, 2016]; Available from:
http://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html.
Dickens, L.E., P.L. Collins, and G.W. Wertz, Transcriptional mapping of human
respiratory syncytial virus. J Virol, 1984. 52(2): p. 364-9.
Spann, K.M., et al., Suppression of the induction of alpha, beta, and lambda
interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in
human epithelial cells and macrophages [corrected]. J Virol, 2004. 78(8): p.
4363-9.
Ramaswamy, M., et al., Respiratory syncytial virus nonstructural protein 2
specifically inhibits type I interferon signal transduction. Virology, 2006. 344(2): p.
328-39.
Swedan, S., A. Musiyenko, and S. Barik, Respiratory syncytial virus nonstructural
proteins decrease levels of multiple members of the cellular interferon pathways.
J Virol, 2009. 83(19): p. 9682-93.
Hastie, M.L., et al., The human respiratory syncytial virus nonstructural protein 1
regulates type I and type II interferon pathways. Mol Cell Proteomics, 2012.
11(5): p. 108-27.
Lo, M.S., R.M. Brazas, and M.J. Holtzman, Respiratory syncytial virus
nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and
alpha/beta interferon responsiveness. J Virol, 2005. 79(14): p. 9315-9.
Elliott, J., et al., Respiratory syncytial virus NS1 protein degrades STAT2 by
using the Elongin-Cullin E3 ligase. J Virol, 2007. 81(7): p. 3428-36.
Straub, C.P., et al., Mutation of the elongin C binding domain of human
respiratory syncytial virus non-structural protein 1 (NS1) results in degradation of
NS1 and attenuation of the virus. Virol J, 2011. 8: p. 252.

89

60.
61.
62.

63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.

Lifland, A.W., et al., Human respiratory syncytial virus nucleoprotein and
inclusion bodies antagonize the innate immune response mediated by MDA5 and
MAVS. J Virol, 2012. 86(15): p. 8245-58.
Bukreyev, A., L. Yang, and P.L. Collins, The secreted G protein of human
respiratory syncytial virus antagonizes antibody-mediated restriction of replication
involving macrophages and complement. J Virol, 2012. 86(19): p. 10880-4.
Bukreyev, A., et al., The secreted form of respiratory syncytial virus G
glycoprotein helps the virus evade antibody-mediated restriction of replication by
acting as an antigen decoy and through effects on Fc receptor-bearing
leukocytes. J Virol, 2008. 82(24): p. 12191-204.
Tripp, R.A., et al., CX3C chemokine mimicry by respiratory syncytial virus G
glycoprotein. Nat Immunol, 2001. 2(8): p. 732-8.
Oshansky, C.M., et al., Respiratory syncytial virus proteins modulate suppressors
of cytokine signaling 1 and 3 and the type I interferon response to infection by a
toll-like receptor pathway. Viral Immunol, 2009. 22(3): p. 147-61.
Monick, M.M., et al., Respiratory syncytial virus up-regulates TLR4 and
sensitizes airway epithelial cells to endotoxin. J Biol Chem, 2003. 278(52): p.
53035-44.
Arnold, R. and W. Konig, Respiratory syncytial virus infection of human lung
endothelial cells enhances selectively intercellular adhesion molecule-1
expression. J Immunol, 2005. 174(11): p. 7359-67.
Eisenhut, M., Extrapulmonary manifestations of severe respiratory syncytial virus
infection--a systematic review. Crit Care, 2006. 10(4): p. R107.
Panuska, J.R., et al., Productive infection of isolated human alveolar
macrophages by respiratory syncytial virus. J Clin Invest, 1990. 86(1): p. 113-9.
Ugonna, K., et al., Macrophages Are Required for Dendritic Cell Uptake of
Respiratory Syncytial Virus from an Infected Epithelium. PLoS ONE, 2014. 9(3):
p. e91855.
Hobson, L. and M.L. Everard, Persistent of respiratory syncytial virus in human
dendritic cells and influence of nitric oxide. Clin Exp Immunol, 2008. 151(2): p.
359-66.
Johnson, T.R., et al., Primary human mDC1, mDC2, and pDC dendritic cells are
differentially infected and activated by respiratory syncytial virus. PLoS One,
2011. 6(1): p. e16458.
Ajamian, F., et al., Respiratory syncytial virus induces indoleamine 2,3dioxygenase activity: a potential novel role in the development of allergic
disease. Clin Exp Allergy, 2015. 45(3): p. 644-59.
Halfhide, C.P., et al., Respiratory Syncytial Virus Binds and Undergoes
Transcription in Neutrophils From the Blood and Airways of Infants With Severe
Bronchiolitis. Journal of Infectious Diseases, 2011. 204(3): p. 451-458.
Lindemans, C.A., et al., Respiratory syncytial virus inhibits granulocyte apoptosis
through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism.
J Immunol, 2006. 176(9): p. 5529-37.
O'Donnell, D.R., et al., Respiratory syncytial virus RNA in cells from the
peripheral blood during acute infection. Journal of Pediatrics, 1998. 133(2): p.
272-274.

90

76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.

Rezaee, F., et al., Respiratory Syncytial Virus Infection in Human Bone Marrow
Stromal Cells. Am. J. Respir. Cell Mol. Biol., 2011. 45(2): p. 277-286.
Prockop, D.J., Marrow stromal cells as stem cells for nonhematopoietic tissues.
Science, 1997. 276(5309): p. 71-4.
Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal stem
cells. Science, 1999. 284(5411): p. 143-7.
Delorme, B., et al., The human nose harbors a niche of olfactory
ectomesenchymal stem cells displaying neurogenic and osteogenic properties.
Stem Cells Dev, 2010. 19(6): p. 853-66.
Jakob, M., et al., Human nasal mucosa contains tissue-resident immunologically
responsive mesenchymal stromal cells. Stem Cells Dev, 2010. 19(5): p. 635-44.
Girard, S.D., et al., Isolating nasal olfactory stem cells from rodents or humans. J
Vis Exp, 2011(54).
Cho, K.S., et al., Human ethmoid sinus mucosa: a promising novel tissue source
of mesenchymal progenitor cells. Stem Cell Res Ther, 2014. 5(1): p. 15.
Caplan, A.I., Adult mesenchymal stem cells for tissue engineering versus
regenerative medicine. J Cell Physiol, 2007. 213(2): p. 341-7.
Chamberlain, G., et al., Concise review: mesenchymal stem cells: their
phenotype, differentiation capacity, immunological features, and potential for
homing. Stem Cells, 2007. 25(11): p. 2739-49.
Aggarwal, S. and M.F. Pittenger, Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood, 2005. 105(4): p. 1815-22.
Bassi, E.J., C.A. Aita, and N.O. Camara, Immune regulatory properties of
multipotent mesenchymal stromal cells: Where do we stand? World J Stem Cells,
2011. 3(1): p. 1-8.
Lee, R.H., et al., Therapeutic Factors Secreted by Mesenchymal Stromal Cells
and Tissue Repair. Journal of Cellular Biochemistry, 2011. 112(11): p. 30733078.
Bassi, E.J., et al., Exploring the role of soluble factors associated with immune
regulatory properties of mesenchymal stem cells. Stem Cell Rev, 2012. 8(2): p.
329-42.
Tasso, R., et al., Mesenchymal Stem Cells induce functionally active T regulatory
lymphocytes in a paracrine fashion and ameliorate Experimental Autoimmune
Uveitis. Investigative Ophthalmology & Visual Science, 2012.
Larsen, S. and I.D. Lewis, Potential therapeutic applications of mesenchymal
stromal cells. Pathology, 2011. 43(6): p. 592-604.
Lucchini, G., et al., Mesenchymal stromal cells do not increase the risk of viral
reactivation nor the severity of viral events in recipients of allogeneic stem cell
transplantation. Stem Cells Int, 2012. 2012: p. 690236.
Raffaghello, L., et al., Human mesenchymal stem cells inhibit neutrophil
apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem
Cells, 2008. 26(1): p. 151-62.
Rasband, W.S., ImageJ. U. S. National Institutes of Health, Bethesda, Maryland,
USA, 1997-2014.

91

94.
95.
96.
97.
98.

99.
100.
101.

102.
103.

104.

105.
106.
107.
108.

Miller, L. Analyzing gels and western blots with ImageJ. 2010; Available from:
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-withimage-j/.
Kumar, S., et al., Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a
Novel Series of Potent Naphthoquinone-Based Inhibitors. Journal of medicinal
chemistry, 2008. 51(6): p. 1706-1718.
Cheng, K., X. Wang, and H. Yin, Small-Molecule Inhibitors of the TLR3/dsRNA
Complex. Journal of the American Chemical Society, 2011. 133(11): p. 37643767.
Qi, J., et al., Painful Pathways Induced by TLR Stimulation of Dorsal Root
Ganglion Neurons. The Journal of Immunology, 2011. 186(11): p. 6417-6426.
Arrevillaga, G., et al., Respiratory syncytial virus persistence in macrophages
downregulates intercellular adhesion molecule-1 expression and reduces
adhesion of non-typeable Haemophilus influenzae. Intervirology, 2012. 55(6): p.
442-50.
Guerrero-Plata, A., E. Ortega, and B. Gomez, Persistence of respiratory syncytial
virus in macrophages alters phagocytosis and pro-inflammatory cytokine
production. Viral Immunol, 2001. 14(1): p. 19-30.
Guerrero-Plata, A., et al., Antigen presentation by a macrophage-like cell line
persistently infected with respiratory syncytial virus. Virus Res, 2004. 99(1): p.
95-100.
Martinez, I., et al., Cultures of HEp-2 cells persistently infected by human
respiratory syncytial virus differ in chemokine expression and resistance to
apoptosis as compared to lytic infections of the same cell type. Virology, 2009.
388(1): p. 31-41.
Peebles, R.S., Jr. and B.S. Graham, Pathogenesis of respiratory syncytial virus
infection in the murine model. Proc Am Thorac Soc, 2005. 2(2): p. 110-5.
Tripp, R.A., et al., Peripheral Blood Mononuclear Cells from Infants Hospitalized
Owing to Respiratory Syncytial Virus Infection Express T Helper-1 and T Helper2 Cytokines and CC Chemokine Messenger RNA. Journal of Infectious
Diseases, 2002. 185(10): p. 1388-1394.
Welliver, R.C., R.P. Garofalo, and P.L. Ogra, Beta-chemokines, but neither T
helper type 1 nor T helper type 2 cytokines, correlate with severity of illness
during respiratory syncytial virus infection. Pediatr Infect Dis J, 2002. 21(5): p.
457-61.
Miller, A.L., T.L. Bowlin, and N.W. Lukacs, Respiratory syncytial virus-induced
chemokine production: linking viral replication to chemokine production in vitro
and in vivo. J Infect Dis, 2004. 189(8): p. 1419-30.
Bendelja, K., et al., Predominant type-2 response in infants with respiratory
syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. Clin Exp
Immunol, 2000. 121(2): p. 332-8.
Schuijs, M.J., et al., Cytokine targets in airway inflammation. Curr Opin
Pharmacol, 2013. 13(3): p. 351-61.
van Schaik, S.M., R.C. Welliver, and J.L. Kimpen, Novel pathways in the
pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol, 2000.
30(2): p. 131-8.

92

109.
110.
111.
112.
113.
114.

115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.

Alwan, W.H., F.M. Record, and P.J. Openshaw, Phenotypic and functional
characterization of T cell lines specific for individual respiratory syncytial virus
proteins. J Immunol, 1993. 150(12): p. 5211-8.
Alwan, W.H., W.J. Kozlowska, and P.J. Openshaw, Distinct types of lung disease
caused by functional subsets of antiviral T cells. J Exp Med, 1994. 179(1): p. 819.
de Almeida Nagata, D.E., et al., IL-27R-mediated regulation of IL-17 controls the
development of respiratory syncytial virus-associated pathogenesis. Am J Pathol,
2014. 184(6): p. 1807-18.
Petersen, B.C., et al., IL-17E (IL-25) and IL-17RB promote respiratory syncytial
virus-induced pulmonary disease. J Leukoc Biol, 2014.
Reed, M., et al., Deficiency of autophagy protein Map1-LC3b mediates IL-17dependent lung pathology during respiratory viral infection via ER stressassociated IL-1. Mucosal Immunol, 2015. 8(5): p. 1118-30.
Cautivo, K.M., et al., Efficient Lung Recruitment of Respiratory Syncytial VirusSpecific Th1 Cells Induced by Recombinant Bacillus Calmette-Guérin Promotes
Virus Clearance and Protects from Infection. The Journal of Immunology, 2010.
185(12): p. 7633-7645.
Stokes, K.L., et al., Differential pathogenesis of respiratory syncytial virus clinical
isolates in BALB/c mice. J Virol, 2011. 85(12): p. 5782-93.
Moore, M.L., et al., A chimeric A2 strain of respiratory syncytial virus (RSV) with
the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and
airway dysfunction. J Virol, 2009. 83(9): p. 4185-94.
Shimizu, T., et al., Indoleamine 2,3-dioxygenase. Purification and some
properties. Journal of Biological Chemistry, 1978. 253(13): p. 4700-6.
Higuchi, K. and O. Hayaishi, Enzymic formation of D-kynurenine from Dtryptophan. Arch Biochem Biophys, 1967. 120(2): p. 397-403.
Taylor, M.W. and G.S. Feng, Relationship between interferon-gamma,
indoleamine 2,3-dioxygenase, and tryptophan catabolism. Faseb j, 1991. 5(11):
p. 2516-22.
Thackray, S.J., C.G. Mowat, and S.K. Chapman, Exploring the mechanism of
tryptophan 2,3-dioxygenase. Biochem Soc Trans, 2008. 36(Pt 6): p. 1120-3.
Forouhar, F., et al., Molecular insights into substrate recognition and catalysis by
tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A, 2007. 104(2): p. 473-8.
Yuasa, H.J., et al., Evolution of vertebrate indoleamine 2,3-dioxygenases. J Mol
Evol, 2007. 65(6): p. 705-14.
Yamazaki, F., et al., Human indolylamine 2,3-dioxygenase. Its tissue distribution,
and characterization of the placental enzyme. Biochem J, 1985. 230(3): p. 635-8.
Munn, D.H., et al., Prevention of allogeneic fetal rejection by tryptophan
catabolism. Science, 1998. 281(5380): p. 1191-3.
Weiss, G., et al., Possible role of cytokine-induced tryptophan degradation in
anaemia of inflammation. Eur J Haematol, 2004. 72(2): p. 130-4.
Leung, B.S., et al., Differential induction of indoleamine-2,3-dioxygenase (IDO)
by interferon-gamma in human gynecologic cancer cells. Cancer Lett, 1992.
66(1): p. 77-81.

93

127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.

138.
139.

140.
141.
142.

Macchiarulo, A., et al., Highlights at the gate of tryptophan catabolism: a review
on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase
(IDO), a novel target in cancer disease. Amino Acids, 2009. 37(2): p. 219-29.
Zelante, T., et al., Indoleamine 2,3-dioxygenase in infection: the paradox of an
evasive strategy that benefits the host. Microbes Infect, 2009. 11(1): p. 133-41.
Orabona, C. and U. Grohmann, Indoleamine 2,3-dioxygenase and regulatory
function: tryptophan starvation and beyond. Methods Mol Biol, 2011. 677: p. 26980.
Habara-Ohkubo, A., et al., Establishment of an antitoxoplasma state by stable
expression of mouse indoleamine 2,3-dioxygenase. Infection and Immunity,
1993. 61(5): p. 1810-1813.
Murakami, Y., et al., Inhibition of increased indoleamine 2,3-dioxygenase activity
attenuates Toxoplasma gondii replication in the lung during acute infection.
Cytokine, 2012. 59(2): p. 245-51.
Daubener, W., et al., Restriction of Toxoplasma gondii growth in human brain
microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase.
Infect Immun, 2001. 69(10): p. 6527-31.
Knubel, C.P., et al., Indoleamine 2,3-dioxigenase (IDO) is critical for host
resistance against Trypanosoma cruzi. Faseb j, 2010. 24(8): p. 2689-701.
Donovan, M.J., et al., Indoleamine 2,3-dioxygenase (IDO) induced by
Leishmania infection of human dendritic cells. Parasite Immunology, 2012.
34(10): p. 464-472.
Larrea, E., et al., Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C
Virus Infection. Journal of Virology, 2007. 81(7): p. 3662-3666.
Yoshida, R., et al., Induction of indoleamine 2,3-dioxygenase in mouse lung
during virus infection. Proc Natl Acad Sci U S A, 1979. 76(8): p. 4084-6.
van der Sluijs, K.F., et al., Influenza-Induced Expression of Indoleamine 2,3Dioxygenase Enhances Interleukin-10 Production and Bacterial Outgrowth during
Secondary Pneumococcal Pneumonia. Journal of Infectious Diseases, 2006.
193(2): p. 214-222.
Huang, L., et al., Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse
Models of Influenza A Virus Infection. PLoS ONE, 2013. 8(6): p. e66546.
Fox, J.M., et al., Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO)
activity modifies pattern recognition receptor expression and proinflammatory
cytokine responses early during influenza virus infection. Journal of Leukocyte
Biology, 2014.
Sage, L.K., et al., Indoleamine 2,3-dioxygenase (IDO) activity during the primary
immune response to influenza infection modifies the memory T cell response to
influenza challenge. Viral Immunol, 2014. 27(3): p. 112-23.
Schroecksnadel, K., et al., Indoleamine-2, 3-dioxygenase and other interferongamma-mediated pathways in patients with human immunodeficiency virus
infection. Curr Drug Metab, 2007. 8(3): p. 225-36.
Adams, O., et al., Role of Indoleamine-2,3-Dioxygenase in Alpha/Beta and
Gamma Interferon-Mediated Antiviral Effects against Herpes Simplex Virus
Infections. Journal of Virology, 2004. 78(5): p. 2632-2636.

94

143.
144.
145.
146.
147.
148.

149.
150.
151.
152.

153.
154.
155.
156.
157.
158.

159.

Godin-Ethier, J., et al., Indoleamine 2,3-dioxygenase expression in human
cancers: clinical and immunologic perspectives. Clin Cancer Res, 2011. 17(22):
p. 6985-91.
Fallarino, F., et al., T cell apoptosis by tryptophan catabolism. Cell Death Differ,
2002. 9(10): p. 1069-77.
Fallarino, F., et al., T cell apoptosis by kynurenines. Adv Exp Med Biol, 2003.
527: p. 183-90.
Xu, H., et al., IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol
Lett, 2008. 121(1): p. 1-6.
Huang, A., et al., Serum tryptophan decrease correlates with immune activation
and impaired quality of life in colorectal cancer. Br J Cancer, 2002. 86(11): p.
1691-6.
Giusti, R.M., et al., Differential patterns of serum biomarkers of immune
activation in human T-cell lymphotropic virus type I-associated
myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma.
Cancer Epidemiol Biomarkers Prev, 1996. 5(9): p. 699-704.
Fallarino, F., et al., Modulation of tryptophan catabolism by regulatory T cells. Nat
Immunol, 2003. 4(12): p. 1206-12.
Puccetti, P. and U. Grohmann, IDO and regulatory T cells: a role for reverse
signalling and non-canonical NF-kappaB activation. Nat Rev Immunol, 2007.
7(10): p. 817-23.
Musso, T., et al., Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression
in human monocytes. Blood, 1994. 83(5): p. 1408-11.
Yuan, W., et al., Modulation of cellular tryptophan metabolism in human
fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine
2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell
Physiol, 1998. 177(1): p. 174-86.
Liebau, C., et al., Interleukin-12 and interleukin-18 induce indoleamine 2,3dioxygenase (IDO) activity in human osteosarcoma cell lines independently from
interferon-gamma. Anticancer Res, 2002. 22(2a): p. 931-6.
Pallotta, M.T., et al., Indoleamine 2,3-dioxygenase is a signaling protein in longterm tolerance by dendritic cells. Nat Immunol, 2011. 12(9): p. 870-878.
Chen, W., IDO: more than an enzyme. Nat Immunol, 2011. 12(9): p. 809-811.
Boasso, A., et al., HIV inhibits CD4+ T-cell proliferation by inducing indoleamine
2,3-dioxygenase in plasmacytoid dendritic cells. Blood, 2007. 109(8): p. 3351-9.
Orabona, C., M.T. Pallotta, and U. Grohmann, Different partners, opposite
outcomes: a new perspective of the immunobiology of indoleamine 2,3dioxygenase. Mol Med, 2012. 18: p. 834-42.
Clark, K., et al., Use of the Pharmacological Inhibitor BX795 to Study the
Regulation and Physiological Roles of TBK1 and IκB Kinase ε: A DISTINCT
UPSTREAM KINASE MEDIATES SER-172 PHOSPHORYLATION AND
ACTIVATION. The Journal of Biological Chemistry, 2009. 284(21): p. 1413614146.
Blasius, A.L. and B. Beutler, Intracellular toll-like receptors. Immunity, 2010.
32(3): p. 305-15.

95

160.
161.
162.
163.
164.
165.

166.
167.
168.
169.
170.
171.
172.
173.
174.
175.

Hacker, H., et al., CpG-DNA-specific activation of antigen-presenting cells
requires stress kinase activity and is preceded by non-specific endocytosis and
endosomal maturation. Embo j, 1998. 17(21): p. 6230-40.
Hackstein, H., et al., The TLR7/8 ligand resiquimod targets monocyte-derived
dendritic cell differentiation via TLR8 and augments functional dendritic cell
generation. Cell Immunol, 2011. 271(2): p. 401-12.
Lenert, P.S., Classification, mechanisms of action, and therapeutic applications
of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators
Inflamm, 2010. 2010: p. 986596.
Stunz, L.L., et al., Inhibitory oligonucleotides specifically block effects of
stimulatory CpG oligonucleotides in B cells. European Journal of Immunology,
2002. 32(5): p. 1212-1222.
Kim, H.W., et al., Respiratory syncytial virus disease in infants despite prior
administration of antigenic inactivated vaccine. Am J Epidemiol, 1969. 89(4): p.
422-34.
Murphy, B.R., et al., Enhanced pulmonary histopathology is observed in cotton
rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or
purified F glycoprotein and challenged with RSV 3-6 months after immunization.
Vaccine, 1990. 8(5): p. 497-502.
Prince, G.A., et al., Enhancement of respiratory syncytial virus pulmonary
pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted
virus. J Virol, 1986. 57(3): p. 721-8.
Belshe, R.B., et al., Experimental respiratory syncytial virus infection of four
species of primates. J Med Virol, 1977. 1(3): p. 157-62.
Kakuk, T.J., et al., A human respiratory syncytial virus (RSV) primate model of
enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine
but not a recombinant FG subunit vaccine. J Infect Dis, 1993. 167(3): p. 553-61.
Papin, J.F., et al., Infant baboons infected with respiratory syncytial virus develop
clinical and pathological changes that parallel those of human infants. Vol. 304.
2013. L530-L539.
Byrd, L.G. and G.A. Prince, Animal Models of Respiratory Syncytial Virus
Infection. Clinical Infectious Diseases, 1997. 25(6): p. 1363-1368.
Prince, G.A., et al., The pathogenesis of respiratory syncytial virus infection in
cotton rats. The American Journal of Pathology, 1978. 93(3): p. 771-791.
Prince, G.A., et al., Respiratory syncytial virus infection in inbred mice. Infection
and Immunity, 1979. 26(2): p. 764-766.
Graham, B.S., et al., Primary respiratory syncytial virus infection in mice. J Med
Virol, 1988. 26(2): p. 153-62.
Mallela, J., et al., Natriuretic peptide receptor A signaling regulates stem cell
recruitment and angiogenesis: a model to study linkage between inflammation
and tumorigenesis. Stem Cells, 2013. 31(7): p. 1321-9.
Yui, I., et al., Detection of human respiratory syncytial virus sequences in
peripheral blood mononuclear cells. Journal of Medical Virology, 2003. 70(3): p.
481-489.

96

176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.

189.
190.
191.
192.

Ajamian, F., et al., Respiratory syncytial virus replication induces Indoleamine 2,
3-dioxygenase (IDO) activation in human dendritic cells. Allergy, Asthma &
Clinical Immunology, 2010. 6: p. 1-2.
de Graaff, P.M., et al., Respiratory syncytial virus infection of monocyte-derived
dendritic cells decreases their capacity to activate CD4 T cells. J Immunol, 2005.
175(9): p. 5904-11.
Rezaee, F., et al., Respiratory Syncytial Virus Alters Human Bone Marrow
Stromal Cell Function. Am. J. Respir. Crit. Care Med., 2010.
181(1_MeetingAbstracts): p. A2502-.
Meyerholz, D.K., et al., Reduced clearance of respiratory syncytial virus infection
in a preterm lamb model. Microbes and Infection, 2004. 6(14): p. 1312-1319.
Lin, H., et al., Air-liquid interface (ALI) culture of human bronchial epithelial cell
monolayers as an in vitro model for airway drug transport studies. J Pharm Sci,
2007. 96(2): p. 341-50.
Welliver, T.P., J.L. Reed, and R.C. Welliver, Sr., Respiratory syncytial virus and
influenza virus infections: observations from tissues of fatal infant cases. Pediatr
Infect Dis J, 2008. 27(10 Suppl): p. S92-6.
Furze, R.C. and S.M. Rankin, The role of the bone marrow in neutrophil
clearance under homeostatic conditions in the mouse. The FASEB Journal,
2008. 22(9): p. 3111-3119.
Rankin, S.M., The bone marrow: a site of neutrophil clearance. Journal of
Leukocyte Biology, 2010. 88(2): p. 241-251.
Cassatella, M.A., et al., Toll-like receptor-3-activated human mesenchymal
stromal cells significantly prolong the survival and function of neutrophils. Stem
Cells, 2011. 29(6): p. 1001-11.
Delarosa, O., W. Dalemans, and E. Lombardo, Toll-like receptors as modulators
of mesenchymal stem cells. Front Immunol, 2012. 3: p. 182.
Giuliani, M., et al., TLR ligands stimulation protects MSC from NK killing. Stem
Cells, 2014. 32(1): p. 290-300.
Le Blanc, K. and D. Mougiakakos, Multipotent mesenchymal stromal cells and
the innate immune system. Nat Rev Immunol, 2012. 12(5): p. 383-96.
Opitz, C.A., et al., Toll-Like Receptor Engagement Enhances the
Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal
Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-β and
Protein Kinase R. Stem Cells, 2009. 27(4): p. 909-919.
Raicevic, G., et al., Inflammation modifies the pattern and the function of Toll-like
receptors expressed by human mesenchymal stromal cells. Hum Immunol, 2010.
71(3): p. 235-44.
Haynes, L.M., et al., Involvement of Toll-Like Receptor 4 in Innate Immunity to
Respiratory Syncytial Virus. Journal of Virology, 2001. 75(22): p. 10730-10737.
Murawski, M.R., et al., Respiratory Syncytial Virus Activates Innate Immunity
through Toll-Like Receptor 2. Journal of Virology, 2009. 83(3): p. 1492-1500.
Chen, G.-Y., et al., Baculovirus Transduction of Mesenchymal Stem Cells
Triggers the Toll-Like Receptor 3 Pathway. Journal of Virology, 2009. 83(20): p.
10548-10556.

97

193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.

van Drunen Littel-van den Hurk, S. and E.R. Watkiss, Pathogenesis of
respiratory syncytial virus. Current Opinion in Virology, 2012. 2(3): p. 300-305.
Takeuchi, O. and S. Akira, Pattern Recognition Receptors and Inflammation.
Cell, 2010. 140(6): p. 805-820.
Abumaree, M., et al., Immunosuppressive Properties of Mesenchymal Stem
Cells. Stem Cell Reviews and Reports, 2012. 8(2): p. 375-392.
Haddad, N.E., Mesenchymal Stem Cells: Immunology and Therapeutic Benefits.
Stem Cells in Clinic and Research. 2011.
Croitoru-Lamoury, J., et al., Interferon-γ Regulates the Proliferation and
Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3
Dioxygenase (IDO). PLoS ONE, 2011. 6(2): p. e14698.
Hissong, B.D., et al., Upregulation of interferon-induced indoleamine 2,3dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl
tripeptide, and interleukin-1. Cell Immunol, 1995. 160(2): p. 264-9.
Fallarino, F., U. Grohmann, and P. Puccetti, Indoleamine 2,3-dioxygenase: from
catalyst to signaling function. Eur J Immunol, 2012. 42(8): p. 1932-7.
Belladonna, M.L., et al., Cutting edge: Autocrine TGF-beta sustains default
tolerogenesis by IDO-competent dendritic cells. J Immunol, 2008. 181(8): p.
5194-8.
Pallotta, M.T., et al., Indoleamine 2,3-dioxygenase is a signaling protein in longterm tolerance by dendritic cells. Nat Immunol, 2011. 12(9): p. 870-8.
Orabona, C., et al., SOCS3 drives proteasomal degradation of indoleamine 2,3dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl
Acad Sci U S A, 2008. 105(52): p. 20828-33.
Schmidt, S.V. and J.L. Schultze, New insights into IDO biology in bacterial and
viral infections. Frontiers in Immunology, 2014. 5.
Meisel, R., et al., Human but not murine multipotent mesenchymal stromal cells
exhibit broad-spectrum antimicrobial effector function mediated by indoleamine
2,3-dioxygenase. Leukemia, 2011. 25(4): p. 648-54.
Ren, G., et al., Species variation in the mechanisms of mesenchymal stem cellmediated immunosuppression. Stem Cells, 2009. 27(8): p. 1954-62.
Ling, W., et al., Mesenchymal stem cells use IDO to regulate immunity in tumor
microenvironment. Cancer Res, 2014. 74(5): p. 1576-87.
Bem, R.A., J.B. Domachowske, and H.F. Rosenberg, Animal models of human
respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol, 2011.
301(2): p. L148-56.
Domachowske, J.B., C.A. Bonville, and H.F. Rosenberg, Animal models for
studying respiratory syncytial virus infection and its long term effects on lung
function. Pediatr Infect Dis J, 2004. 23(11 Suppl): p. S228-34.
Kong, X., et al., An immunocompromised BALB/c mouse model for respiratory
syncytial virus infection. Virol J, 2005. 2: p. 3.
Hashemi, S.M., et al., Comparative immunomodulatory properties of adiposederived mesenchymal stem cells conditioned media from BALB/c, C57BL/6, and
DBA mouse strains. J Cell Biochem, 2013. 114(4): p. 955-65.

98

211.

Ringe, J., et al., Towards in situ tissue repair: human mesenchymal stem cells
express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon
stimulation with CXCL8 but not CCL2. J Cell Biochem, 2007. 101(1): p. 135-46.

99

